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Abstract 
Background. Longitudinal studies usually evaluate risk by modelling time to first event 
using standard Cox's regression. However this method fails to utilize further outcome 
information after the first event. In patients with Chronic Kidney Disease repeated events 
of the same type (recurrent events) and or different type (multiple events) occur 
frequently. Risk estimation based on partial information may be inaccurate and 
imprecise. Yet, the analytical tool must take into account the lack of independence of the 
failure times. 
Methods. To determine whether other methods of analysis are more infonnative and 
powerful than standard Cox's regression I re-evaluated data from previous research I had 
undertaken in Chronic Kidney Disease patients. Data from a multi-centre dialysis access 
study of incident hemodialysis patients were used as an example ofrecun·ent failure 
events. Data from a cohort of pre-dialysis patients were used as an example of multiple 
competing events (dialysis start and death). Correlation in the data was accounted for 
using either robust variance methods or incorporating frailty effects into the model. 
Different approaches were used more or less free from distributional assumptions, 
including generalized models for counts, and using the robust version of the Cox's model 
as reference estimation method. 
II 
Results. The work shows that standard survival techniques that disregarded further 
information after the first event have limitations, in terms of power (precision of each 
estimate and number of estimated effects) and possibly of accuracy (bias). For example, 
the hazard ratio (HR) of primary failure of the first arterio-venous access for dialysis was 
1.96 (95% Confidence Intervals 0.93 to 4.1) in presence of both history of heart failure 
and nephrology follow-up shorter than 3 months before dialysis statt (effect of the 
interaction controlling for the main effects and other covariates). The estimate was more 
precise in the corresponding extended Cox's model for recurrent events (HR 2.02, 95% 
Cl 1.11 to 3.65). Similar fits were obtained using variance corrected parametric models. 
However, all these variance corrected models did not take into account any random 
effects. This may have induced underestimation of the true effects ifthe frailty models 
were true (HR from the frailty Weibull model 3.5, 95% CI from 1.34 to 9). Improvement 
of model efficiency and more flexibility in model building were observed also using 
competing ri k models for multiple events. 
Conclusion. Analytical techniques for repeated events exist that make more efficient the 
use of longitudinal data while accounting for their correlation. These methods help 
address research questions about risk (and some also survival time) considering the entire 
course of a disease process or multiple possible outcomes, and have implications on 
design, implementation and costs of clinical research. 
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1) Chapter 1: Problem statement and thesis outline 
Chapter overview 
This first chapter introduces the issues of repeated events in longitudinal studies, and 
provides a general overview of the thesis work. 
2 
1. Introduction 
1. Problem to be addressed 
Longitudinal designs are often used to measure observation time and record event 
occurrence during the study period. The risk of a failure event (or the probability of a 
successful outcome such as disease remission) can be estimated from such measurements 
using different analytical techniques. One common complication of longitudinal designs 
is that the event of interest may recur or compete with other events. This is the case, for 
example, when repeated failure events may recur in the same subject (e.g., repeated 
urinary tract infections or repeated flares of an inflammatory disease) or when competing 
risks are correlated (e.g., dialysis and cardiovascular events in subjects with Chronic 
Kidney Disease). In these circumstances, data are not independent because they come 
from the same individuals, and standard regression techniques can not be used unless 
only partial information is considered such as one single observation per subject. 
In the recent years I have carried out analyses of several longitudinal studies of patients 
with kidney disease. Before enrolling in the PhD program I extensively applied standard 
survival methods for risk estimation (1 - 4). However, as I will illustrate in this thesis, in 
nephrology, as in other areas of clinical research, correlation of risk data is often the rule 
rather than the exception. Examples of where this may arise in nephrology include 
repeated episodes of acute kidney injury in subjects with cardiovascular disease 
undergoing angiographic procedures, repeated peritonitis in peritoneal dialysis patients, 
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rejection or infection episodes in kidney transplant patients, and dialysis catheter 
infections or dysfunction and arterio-venous access thrombosis in hemodialysis patients. 
The presence of correlation in such data is related to the existence of repeated or multiple 
observations from the same individuals, which requires more sophisticated statistical 
approaches. Further examples are offered in the second section of this introductory 
chapter. 
During my PhD program, I completed other studies addressing a variety of questions 
relevant to understanding kidney diseases, including competing risks (5 - 8). For the 
purpose of this thesis I have reviewed some of the dialysis access data I already published 
using standard techniques for single observations per subject (3), and compared them 
with more appropriate analytical approaches to repeated event processes. I also expanded 
on competing risks in a Chronic Kidney Disease longitudinal cohort study (8). 
n. Work outline 
The second chapter of the thesis introduces standard regression methods for risk 
estimation, and some challenges posed by longitudinal designs. Some of the content of 
this and subsequent chapters (chapter 3 and 4) was published as a series of 5 papers in 
Nephrology Dialysis and Transplantation of which I was the first and corresponding 
author (9 - 13). Standard methods are appropriate for the analysis of independent events, 
such as the first failure episode of a recurrent process (e.g., repeated hospitalizations) or 
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one event only from multiple possible failure episodes of different type (e.g., dialysis and 
myocardial infarction). These standard methods can be used to model count outcomes or 
survival times, using non parametric, semi-parametric and fully parametric regression 
models. 
The subsequent chapters introduce the general approach to correlated data, the possible 
sources of correlation, and the theory and implications of the main analytical methods for 
survival and count data (chapters 3 and 4). Chapters 5 and 6 provide examples of 
modelling using previously published data. Results are presented and discussed along 
with the strength and weaknesses of each possible approach, and its consistency with the 
study question and design. Each of these analyses illustrates the methodological 
challenges in analysing longitudinal data and the solutions that may be considered to deal 
with them. On the basis of my findings I conclude this thesis work with some comments 
and recommendations for researchers facing similar m~thodological challenges as to how 
best deal with these problems (chapter 7). 
111 . Study data discussed in this thesis work 
To introduce standard semi-parametric and parametric regression models (chapter 2) I 
used examples from an Italian multi-centre study on hemo<lialysis vascular accesses (3). 
Study definitions, methods and results are reported at the beginning ofthe chapter. I 
designed the study and published the data as principal and corresponding author. As 
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mentioned above, vascular access thrombosis may recur in the same individual several 
times as one patient may have several vascular accesses. However, at the time of the 
study I was unaware of the existence of techniques capable to account for the correlation 
of repeated observations per subject, and only the analysis of the frrst access was reported 
in the paper. In subsequent years I studied this correlation problem and found ways to 
use Cox's regression for both repeated failure events of the same type (such as dialysis 
access thrombosis) and of different types (such as dialysis and death in chronic kidney 
disease patients). More recent publications are based on the analy is of time varying 
exposures and competing risks using Cox's regression (5 - 8). I designed and analysed 
the data from all of these studies, being the first author in three of them. One of these 
studies evaluates the impact of Vitamin D levels on the risk of renal and patient death and 
it is used as an example of competing risks in chapter 5 (8). Also for this study, 
defmitions, methods and results of the main publication are described in chapter 5. For 
semi-parametric (chapter 5) and parametric (chapter 6) analyses of repeated events of the 
same type, I used the vascular access data as examples, including information not 
included in the original published report (3). The same data are used also to run count 
models. This may represent a limitation, as censored survival data may contain excess 
"zero counts" when using event history data as opposed to aggregated data. 
IV. Statistical packages used for the analyses 
The statistical packages I used for this thesis work are STAT A and R. 
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STAT A: StataCorp. 2007. Stata Statistical Software: Release 10. College Station, TX: 
StataCorp LP; web site: www.stata.com 
R: R Development Core Team (2009). R: A language and environment for tatistical 
computing. R Foundation for Statistical Computing, Vienna, Austria. ISBN 3-900051-07-
0, URL http://www.R-project.org. Website for software download: http://cran.r-
project.org/ 
Both packages offer an easy programming interface based on text files. STAT A is more 
friendly for management oflarge data sets. R (which is a "dialect" of S-Pius) allows more 
flexibility of use and generates better plots. For example, at the time of this thesis work 
one of the limitation ofSTATA is the impossibility to run stratified frailty models (either 
semi-parametric or parametric survival models). One of the greatest advantages of R is 
the free source, including several updates per year. Both have free online educational 
resources including discussion group and technical support. 
What I learnt after my initial experience with other packages and from this thesis work, is 
that serious analysis cannot be done with only one statistical package or avoiding some 
minimal programming work. Both STAT A and Rare excellent tools and together offer 
most of the necessary support for risk estimation in longitudinal studies. 
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2. Correlated data 
i. Study designs generating correlated data 
Much medical research can be simplified as the study of an exposure-disease relationship 
(9, 1 0). In some study designs the association between exposure and disease is assessed 
more than once on the same subject or group of people. Multiple measures can be taken 
under different experimental conditions in cross-sectional studies or longitudinally over 
time. For example, in a cross-sectional study of endothelial function, brachial artery flow 
rates can be measured in the same subject under exposure to different vasoactive 
substances. Researchers are interested in differences in flow rates by level of the 
exposure (i.e., the effect of one or more vasoactive drugs versus control or reference 
standard). Unbiased estimates of such effect(s) can be obtained removing from the 
overall (unconditional) variation of the response both the variability between subjects due 
to measured subject level characteristics affecting the outcome, and the within subject 
variability due to the dependencies of the repeated measures taken on the same subject. 
The residual variability (random error variability) is what remains to be explained after 
the model has been fitted. Failure to account for the "extra-variability" in the data may 
result in biased estimates of the effects of interest and their standard errors. This variance 
component approach to the analysis of correlated data can be extended also to risk data. 
Longitudinal studies typically monitor participants over time and both predictors (e.g., 
blood pressure) and outcomes (e.g., left ventricular mass index) are measured in different 
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occasions in the same subject. In some designs, observations can fall into groups 
(clustered data). This occurs when single measurements are taken on a paired organ (e.g., 
the eye or the kidney) or on different members of the same hospital, region or family. 
More complex designs may lead to a combination of clustering and repeated I 
longitudinal measuring. For example, a longitudinal multi-centre study of non fatal 
cardiovascular (CV) events in patients with Chronic Kidney Disease (CKD) will generate 
outcome data recurring in the same subject and in the same centre. Table 1 shows 
examples of how data generated by these study designs can be set up for analysis. In all 
these longitudinal designs part of the variability of the response under study is due to 
unobserved cluster or unmeasured subject level characteristics that can and should be 
taken into account. 
11. Origin of correlation 
Outcome data generated from such clustered and I or repeated I longitudinal study 
designs are correlated because it is possible to identify patterns of association within 
individuals or clusters. In other words, multiple measurements on the same subjects or 
single assessments of paired organs or members of the same hospitals, region or family 
generate values that are closer than those obtained from different individuals, organs, 
hospital, regions or families. In fact different organs of the same subject and different 
individuals of the same community share biologic experiences, environmental exposures 
and genetic background. Factors underlying such correlation are often unknown or 
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- -------------------------------------------------------------------------
Table 1: Examples of correlated (panel) data sets: Each study participant can be 
assessed once or in several occasions, in random sequence (repeated measures) or over 
time (longitudinal data). Each row in the panels represents an observation, with single 
measurements per subject (left) or updated values (right) of both predictors (X) and 
outcomes (e.g., mean arterial pressure values - J]. Predictors can be time invariant 
(such as gender, age at baseline or presence of diabetes - Xti) or time varying, i.e. 
assume different values (e.g., glucose - Xtv). In either case, observations can belong or 
not to clusters (CP I CA - present I absent), such as families, schools, or hospitals (lower 
panel). In addition, there can be multilevel data, when clusters are nested in super-
clusters, such as patients (Pt) in physicians (MD) in hospitals (H). In these situations, 
Ievell is the most detailed level (the single observation); level 2 the epidemiological unit 
(the patient); and /eve/3 or higher the next level of hierarchy (membership level). 
Single measurements 
H MD Pt X 
CA 0 
CP 
1 
2 
2 
3 
3 
4 
4 
2 
3 
4 
1 
2 
3 
4 
5 
6 
7 
8 
0 
1 
0 
0 
1 
0 
0 
1 
y 
123 
120 
118 
100 
123 
120 
118 
100 
H 
123 
120 1 
118 1 
100 1 
lO 
Repeated I longitudinal measures 
MD Pt Xti Xtv Y 
1 
2 
2 
2 
2 
1 
2 
2 
2 
2 
3 
3 
4 
4 
0 90 123 
0 
0 
0 
1 
1 
0 
0 
1 
1 
93 125 
110 120 
105 122 
90 123 
93 125 
110 120 
105 122 
90 123 
93 125 
110 120 
105 122 
unmeasured, and may confound the observed relationship of interest. Furthermore, the 
degree of correlation in the data can vary and its sign is not necessarily positive. Indeed 
for some outcomes such as infection disease recurrence, previous experience may induce 
negative correlation. In all cases, once a measurement value has been obtained further 
values within the same individual or cluster can be more accurately "guessed". In other 
words, the within individual I cluster variance differs from the between individual I 
cluster variance. This implies that the corresponding errors - or deviates from the mean -
are no longer due to chance alone causing excess variability in the data or heterogeneity 
(Figure 1). In these situations traditional regression methods are inappropriate as they 
assume independent errors (11 , 12). 
111. Analytical approaches 
Two major analytical approaches exist for the analysis of correlated data: random effect 
modelling and variance corrected methods (13). The main assumption underlying these 
approaches is that the responses are correlated within subject I cluster, but independent 
between subject I cluster. These two approaches can be applied to outcome of different 
types, i.e. generalized linear (continuous, binary and count outcomes) as well as time-to-
event (survival) data. The present thesis work will consider both generalized linear 
models for count outcomes and survival analysis techniques because risks in longitudinal 
studies can be estimated from either rates of event count or survival times depending on 
the way the response has been measured. However, it is important to note that all models 
11 
Lack of correlation 
Between clusters 
Within cluster 
Dependency 
~ 
Exposure variable (x) 
Figure I: Repeated observations within the same individual or single measurements 
obtained from clusters (groups of dots) increase the heterogeneity of the study sample 
(larger oval delimited by a dashed line). Residuals (deviates of each observation point 
from the mean - continuous straight line) are dependent within individuals or clusters 
and independent between individuals or clusters. Failure to acknowledge these 
dependencies and group heterogeneity may result in biased estimates of the model 
coefficients (in the example the intercept and the slope of the line describing the average 
change in y as x changes). 
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for rates and some survival models are "parametric models". For example, the Poisson 
process is characterized by a slow and constant event rate with event count variance equal 
to the mean. Parametric survival models assume that the observed failure times have 
been randomly drawn from some specific distributions. Since these assumptions are 
often violated or some requirements not met, the Cox's model has become the most 
popular approach to estimate risks in longitudinal studies. The Cox's model is in fact a 
"semi-parametric" model because the effects (relative risks) are estimated without 
making any assumption about the distribution of the failure times. When the observed 
risk distribution is well described by a specific parametric model (and the underlying 
biological and clinical process are consistent with how the risk is supposed to vary over 
time according to that distribution), that model will make better use of the data in terms 
of efficiency (precision). 
The following sections will summarize the main principles of traditional risk estimation 
methods in longitudinal studies using examples from previous publications (1 - 4). 
Alternative approaches for repeated or multiple events are subsequently introduced and 
applied to the same data or data from other studies (5 - 8). 
13 
2) Chapter 2: Standard modelling approaches 
14 
Chapter overview 
Chapter 2 introduces general principles of risk estimation in longitudinal studies, using 
either count data or survival data. The data used as example are from the vascular access 
study, which is briefly summarized at the beginning ofthe chapter (3). Concepts of risk 
and rates are also explained as well as ways to estimate risk using semi-parametric 
methods and fully parametric methods. 
15 
J. The Italian multi-centre hemodialysis access study 
1. Study description 
The Italian Multi-centre Hemodialysis Access study data consists of 535 incident 
hemodialysis patients receiving an arterio-venous (A V) access for the first time (3). The 
study was designed to study the association between timing of referral to the nephrologi t 
and the risk of A V access failure, controlling for baseline characteristics and presence of 
comorbid conditions. During a 6 year follow-up these patients received 633 A V fistulae 
and 67 grafts (700 A V accesses). The survival data from these individuals record up to 4 
recurrence times: 404 individuals received one AV access, 101 received 2 accesses, 26 
received 3 accesses and 4 received 4 accesses. 
11. Arteriovenous accesses for hemodialysis 
An A V fistula is a communication between an artery and a vein usually created in the 
arm (at the wrist or at the elbow crease). The new vessel keeps some of the desirable 
properties of the vein and the artery: 1) it is superficial with elastic walls which make it 
suitable to repeated needling, and 2) it carries high blood flow rates. These are both 
necessary conditions for maintenance hemodialysis. Alternatively, an A V graft is a 
communication between artery and veins through a prosthetic bridge made of synthetic 
(as in this study) or natural material (human or bovine veins). Also a graft is repeatedly 
cannulated and carries high blood flow rates. However, it contains a foreign material and 
its use has been associated with increased risk of death from infection and cardiovascular 
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diseases. Once created an A V access can fail for several reasons leading to its 
thrombosis (primary failure). If possible, revision interventions (either surgical or 
radiological) are undertaken to salvage the malfunctioning or failing A V access. When 
they are successful the access patency is restored and its (secondary) survival extended 
(14 - 21). 
111. Study outcomes 
In the access study the primary AV access creation was successful in 313 cases. During 
the study period 310 primary (unassisted) AV access failures occurred: 222 failures ofthe 
first AV access created, 72 of the second, 13 of the third and 3 of the fourth. Three 
hundred and fifty nine subjects used their first A V access for the duration of the study 
including those who underwent at least one salvage procedure. There were 245 
secondary (final) access failures (i.e. , failures despite revisions): 176 subjects lost their 
first AV access, 55 lost 2 AV accesses, 11 lost 3 and 3 lost 4 A V accesses (Figure 2). 
IV. Analysis of the first event only 
When an event can recur, such as the thrombosis of an A V access, or multiple events can 
occur such as myocardial infarction or death, longitudinal studies can generate complex 
data. One approach to the analysis of such data is to observe each individual until the 
first event that occurs, disregarding further events after the first. In the case of events of 
different types, studies often estimate the risk of combined end-points considering only 
17 
222 176 I Primary~ Unsuccessful - 13 II 
Failures Revisions 
Primary Unsuccessful 
535 ~ 
Failures Revisions 
First s Creations 30 ~ Third Creations 313 46 45 Primary Successful Switched to 
Successes Revisions Catheters 17 2 
~ ~ Primary Successful -Successes Revisions ,..----- -~ 
359 7 
Secondary 19 Switched to 
Successes Secondary Catheters 
Successes 
55 72 
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Figure 2: Outcomes of the arterio-venous accesses from the access study (3). Up to 4 
attempts were made in 535 subjects. The possible outcomes of each intervention are 
primary success or primary failure. Failed AV accesses may or may not be salvaged 
surgically or with interventional radiology procedures. The final (secondary) lost of an 
A V access may be followed by a further attempt or switch to central venous catheter. 
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the first of two or more possible events (composite end-point). The common approach to 
the analysis of the fistula data reflects this tendency and is based on the standard Cox's 
model ( 1 - 4 ). As a result such studies estimate the risk of failure of the first A V fistula 
only disregarding further study data. For example, in the Italian A V study those few 
subjects (N = 22) who received an A V graft as first access were excluded for power 
reasons. An important consequence of this approach is that the study question addressed 
is: "Which factors affect the risk of failure of the first AV fistula in incident hemodialysis 
patients?". Standard approaches for the analysis of survival or count data can be used to 
answer this question. However, the information regarding small group (e.g., A V grafts) 
and further accesses created in the same patient is ignored by such methods. 
2. Estimating the risk of independent events from count and survival data 
Risk estimation in longitudinal studies can be carried out using regression modelling for 
count outcomes or time-to-event analysis of survival data. Count outcome regression 
methods can be used both for aggregated as well as individual data. In fact, counts can 
be thought of as aggregated versions or summaries of more detailed data on occurrences 
of some kind of event (event-history data). Survival analysis is applicable only if times 
have been measured for each individual. Individual and aggregated data set up examples 
from the access study are shown in Tables 2 and 3. 
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Table 2: individual data set up example (access survival data) : multiple records per 
subject 
ID N LR HF VAS AVG p f P start P _stop s f S start S_stop 
1 No No No No Yes 02/01 /96 04/02/96 No 02/01/96 05/20/98 
2 1 No No No No Yes 03/15/97 03/ 16/97 Yes 03/ 15/97 03116/97 
2 2 No No No No Yes 03/20/97 03/21/97 Yes 03/20/97 03/21/97 
2 3 No No No No No 03/22/97 03/24/97 No 03/22/97 03/24/97 
10 Yes No Yes No Yes 06/21/98 06/28/98 Yes 06/21 /98 06/28/98 
10 2 Yes No Yes No Yes 07/05/98 07/07/98 Yes 07/05/98 07/07/98 
10 3 Yes No Yes Yes Yes 07/12/98 07/ 14/98 Yes 07/ 12/98 07114/98 
10 4 Yes No Yes Yes Yes 07/22/98 07/23/98 Yes 07/22/98 07/23/98 
The table shows 8 of the 700 records from the access survival data. Jd is the patient 
identifier and N is the arteriovenous access number: patient 1 had 1 access only, patient 
2 had 3, and patient 10 had 4 accesses created during the study period. The independent 
variables are all binary (i. e., yes I no): LR = late referral (referral to the nephrologist 
less than 3 months of the dialysis start); HF = history of heart failure; VASC: presence of 
vascular disease (previous clinically documented coronary, cerebral or peripheral 
events); and G = arterio-venous graft (as opposed to A V fistula) . P J and SJ are the 
binary event variables defining the failure status at follow-up end (primary and 
secondary failure). P _Start, P _Stop, S_Start and S_Stop are the dates defining the 
beginning (time zeros) and end of the primary and secondary survival times. 
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Table 3: Aggregated data set up example (access count data) including multiple accesses 
per subjects 
LR HF VASCAVG PMOS P CNT S MOS S CNT 
No No No No 4755.95 94 5718.45 75 
No No No Yes 250.87 10 384.88 6 
No No Yes No 1990.25 60 2415.62 49 
Yes Yes Yes No 158.35 14 215.42 12 
Yes Yes Yes Yes 14.24 3 14.24 3 
The table shows 5 of the 15 possible combinations of the selected indep endent variables 
for the count outcomes (primary event count - P _ CNT, and secondary event count -
S _ CNT) and exposure times in months (primary survival time - P _ MOS and secondary 
survival time - S_MOS). These independent variables are all binary (i.e., yes I no): LR = 
late referral (referral to the nephrologist less than 3 months of the dialysis start); HF = 
history of heart failure; VASC: presence of vascular disease (previous clinically 
documented coronary, cerebral or peripheral events); and AVG =arterio-venous graft 
(as opposed to AV fistula). 
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Table 4-7 show the results of two regression models including the following predictors 
(all nominal binary variables coded "yes" or "no"): late referral to the nephrologist 
(resulting in less than 3 months exposure to specialist care prior to dialysis 
commencement), history of heart failure, presence of vascular disease (previous clinically 
documented coronary, cerebral or peripheral events) and arterio-venous graft (as opposed 
to AV fistula). Other variables were not significant predictors of event occurrence (or 
recurrence) in any model (including centre) and are not considered further for simplicity. 
One important finding of the study was that the maturation time (i.e., the time span 
between creation and first use in those 414 subjects whose AV fistulae were cannulated at 
least once) and the use of catheters were possible intermediate variables in the pathway 
linking late referral and the risk of primary and secondary failure respectively. Since 
these covariates were measured only for the first access, they will also be omitted to 
avoid exclusion of subjects from the analysis and allow comparison of different statistical 
approaches. 
The two models shown in Table 4-7 are standard models of independent events 
estimating the risk of failure of the first A V access created in each study participant. 
Each model passed standard checking tests, including diagnostics, assumption 
verifications, and goodness of fit, sensitivity and residual analyses, which will not be 
discussed here. 
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Table 4: Cox's models of the first access primary survival times in the access study 
MODEL 1: Observations 535; event number 222 (time at risk 8633.775 months) 
Co-variate HR P>lzl 95% Confidence Interval 
LR 1.316 0.096 (0.953 to 1.817) 
HF 1.138 0.546 (0.748 to 1.731) 
HXL 1.957 0.064 (0.961 to 3.985) 
VASC 1.347 0.033 (1.025 to 1.771) 
AVG 1.181 0.613 (0.620 to 2.248) 
MODEL 2: Observations 513; event number 212 (time at risk 8415.458 months) 
Co-variate HR 
LR 1.508 
CVD 1.487 
P>lzl 
0.006 
0.004 
95% Confidence Interval 
(1.123 to 2.024) 
(1.135 to 1.948) 
Legend: HR = hazard ratio; P> lzl two sided P value of the Wald test on the coefficients; 
LR = late referral (referral to the nephrologist less than 3 months of the dialysis start); 
HF = history of heart failure; HXL interaction term between HF and LR; VASC: 
presence of vascular disease (previous clinically documented coronary, cerebral or 
p eripheral events); CVD: presence of any cardiovascular disease (HF and I or VASC); 
and AVG = arterio-venous graft (as opposed to A V fistula). in the second model subjects 
receiving an A VG were excluded (N = 22). 
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Table 5: Cox's models of the first access secondary survival times in the access study 
MODEL 1: Observations 535; event number 176 (time at risk 10531.63 months) 
Co-variate HR P>lzl 95% Confidence Interval 
LR 1.418 0.060 (0.985 to 2.043) 
HF 1.339 0.213 (0.846 to 2.118) 
HXL 1.564 0.260 (0.718 to 3.404) 
VASC 1.408 0.029 (1.035 to 1.916) 
AVG 0.840 0.677 (0.369 to 1.910) 
MODEL 2: Observations 513; event number 170 (time at risk 10137.84 months) 
Co-variate HR 
LR 1.594 
CVD 1.674 
P>izl 
0.005 
0.001 
95% Confidence Interval 
(1.150 to 2.210) 
(1.237 to 2.267) 
Legend: HR =hazard ratio; P>izi two sided P value of the Wald test on the coefficients; 
LR = late referral (referral to the nephrologist less than 3 months of the dialysis start); 
HF =history of heart failure; HXL interaction term between HF and LR; VASC: 
presence of vascular disease (previous clinically documented coronary, cerebral or 
peripheral events); CVD: presence of any cardiovascular disease (HF and I or VASC); 
and AVG =arterio-venous graft (as opposed to AV fistula). in the second model subjects 
receiving an A VG were excluded (N = 22). 
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Table 6: Poisson models of the first access primary failure counts in the access study 
MODEL 1: Observations 12; event number 222 (8633. 775 person-months) 
Co-variate IRR P>lzl 95% Confidence Interval 
LR 1.535 0.009 (1.112to2.119) 
HF 1.116 0.608 (0. 735 to 1.695) 
HXL 2.180 0.032 ( 1.068 to 4.448) 
VASC 1.526 0.003 (1.160 to 2.007) 
AVG 1.640 0.131 (0.862 to 3.120) 
MODEL 2: Observations 8; event number 212 (8415.458 person-months) 
Co-variate HR 
LR 1.839 
CVD 1.641 
P>lzl 
0.016 
0.033 
95% Confidence Interval 
(1.120 to 3.018) 
(1.041 to 2.587) 
Legend: JRR = incidence rate ratio; P>lzl two sided P value of the Wald test on the 
coefficients; LR =late referral (referral to the nephrologist less than 3 months of the 
dialysis start); HF = history of heart failure; HXL interaction term between HF and LR; 
VASC: presence of vascular disease (previous clinically documented coronary, cerebral 
or peripheral events); CVD: presence of any cardiovascular disease (HF and I or 
VASC); and AVG = arterio-venous graft (as opposed to AV fistula). in the second model 
subjects receiving an A VG were excluded (N = 22). 
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Table 7: Poisson models of the first access secondary failure counts in the access study 
MODEL 1: Observations 12; event number 176 (10531.63 person-months) 
Co-variate IRR P>lzl 95% Confidence Interval 
LR 1.597 0.012 (1.1 11 to 2.297) 
HF 1.373 0.174 (0.869 to 2. 169) 
HXL 1.585 0.244 (0.730 to 3.444) 
VASC 1.499 0.010 (1.102 to 2.038) 
AVG 0.879 0.759 (0.387 to 1.999) 
MODEL 2: Observations 8; event number 170 (10137.84 person-months) 
Co-variate HR 
LR 1.832 
CVD 1.760 
P>lzl 
0.005 
0.005 
95% Confidence Interval 
(1.201 to 2.794) 
(1. 189 to 2.606) 
Legend: 1RR = incidence rate ratio; P> lzl two sided P value of the Wald test on the 
coefficients; LR = late referral (referral to the nephrologist less than 3 months of the 
dialysis start); HF = history of heart failure; HXL interaction term between HF and LR; 
VASC: presence of vascular disease (previous clinically documented coronary, cerebral 
or peripheral events); CVD: presence of any cardiovascular disea e (HF and I or 
VASC); and AVG = arterio-venous graft (as opposed to AV fistula). In the second model 
subjects receiving an A VG were excluded (N = 22). 
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The results of primary survival analysis (Table 4) indicate that some of the effects of 
interest were of borderline statistical significance when detailed information on specific 
components of cardiovascular disease was used. Insufficient data were available to study 
the risk associated with AV grafts (model 1). Both late referral and presence of any 
cardiovascular disea e independently predicted worse outcomes, but their statistical 
interaction was not significant (model 2). Relative risks were even higher for secondary 
failure models (Table 5), but again specific components of cardiovascular di ease did not 
reach statistical significance. Poisson analyses of aggregated data show different results 
(Table 6 and 7): a) the risk of primary failure increases over-multiplicatively if subjects 
with history of heart failure are referred late; b) there does not seem to be any interaction 
on the risk of secondary survival; and c) relative risks associated with late referral and 
presence of cardiovascular disease may be greater than those estimated in time-to-event 
models. These differences between traditional survival analysis and count analysis using 
the two most popular models, i.e. the Cox's model and the Poisson model, need to be 
explained before discussing how their extensions can be applied to analyse recurrent or 
multiple events properly. 
3. Estimating rates from count data 
1. Models for count responses 
A popular approach to estimate risks in longitudinal studies is to consider the outcome as 
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a count variable of independent events. Poisson regression, for example, is appropriate 
when the underlying risk for such events is small and constant, but the number of 
individuals is large, and thus the total number of events is considerable. The outcome 
variable is counted over a period of time-at-risk - the principal co-variate in the model 
(exposure time), which is recorded for each observation or aggregated data. Standard 
methods for count outcomes assume that events are independent, that the risk experience 
of the subjects when they are under observation reflects their true risk of failure (i.e. , 
when they leave the study their risk does not change), that the follow-up duration is based 
on disea e severity and that the risks for subjects recruited early and late in the study are 
similar. These are standard validity issues to consider in all longitudinal designs (9, 1 0). 
11. Risks and rates 
The analytical methods for both count and survival time outcomes do not model risks but 
rates. As opposed to risks (event count I persons during a specified period oftime) which 
are dimensionless and range from 0 to 1, rates (A. = event count I person-time) have the 
dimension of I I time and range from 0 to +oo. Risks can be estimated directly in short 
studies where subject follow-up is approximately complete (e.g., studies of contrast 
induced nephropathy). Rates are estimated in longer studies because as the study 
duration increases, fewer subjects have complete follow-up. Rates treat one time unit a 
equivalent to another, regardless of which individual they come from (e.g. , one person 
observed for 10 years and another for 20 years would contribute for a total of 30 person-
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years of follow-up or 30 persons per unit time). Depending on the chosen time unit, the 
same rate can have different numerical values and can exceed 1 (100%). For example, if 
8 cases occur among 36 subjects in 1 month, then the same rate can be expressed as 0.22 
cases per person-month or 2.66 cases per person-year (9, 10). Finally, rate estimates are 
unaffected by the precision of the measurement time scale. If 3 deaths are observed in 10 
subjects and their exposure times are 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 months (bands of 1/12 = 
0.0833 years duration), the event rate is 3/(55*0.0833) = 0.655 per year = 655 deaths per 
1000 person-years. Had the data been updated every day, then the length of the band 
would have been 1 day and there would have been 55*(365.25/ 12) = 1674 bands (units of 
n) of 0.002737 year duration. However, the rate would have been the same, 
3/(1674*0.002737) = 0.655 per year. 
Despite these differences incidence rates can be used to estimate ri ks. In fact if the 
underlying risk is constant and small (e.g., less than 0.2) it can be estimated as the 
product of the estimated rate and the observation time. For example, if 1000 subjects are 
followed for 10 years and experience a mortality rate ofO.Ol per person-year (0.01 year-
1), the risk can be estimated as 0.01 * 10 or 0.1 over 10 years (each individual has a 
probability of 10% to die in 10 years). However, as deaths occur over time the same 
mortality applies to a steadily smaller population at risk. Since this population shrinking 
is neglected in the calculation, the risk approximation of the incidence rate does not work 
well for high risks or very long observation times. Fortunately, risks of interest to 
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clinical epidemiologists are usually small and studies not too long. Similarly incidence 
rate (IR) ratios are interpretable as risk (R) ratios since R 1 I R1 = (IR1 * time) I (lRo * 
time) = IR1 I IRo. An example will clarify why this is important to Poisson regression. 
Suppose that "d" A V access failure (independent) events are observed during "n" person-
years, where dis small as compared ton. For example, considering only the first A V 
access attempted in the access study, 222 primary failure events occurred to 535 
individuals over 8633.774 access-months of follow-up. The observed incidence of 
thrombosis was A.1 = d11n1 = 68 1 1673.183 = 0.0406411 month- ' or40.64 per 1000 
access-months in patients referred late to the nephrologist [ 1] and A.o = do/no = 154 I 
6960.591 = 0.0221246 month- 1 or 22.12 per 1000 access-months in patients followed for 
longer than 3 months before dialysis start [0). The incidence rate ratio of the two groups 
is IRR = A. 1 I A.o = 1.83. Poisson regression can be used to estimate the IRR associated 
with "one unit change" of the predictor (11 , 12). Poisson regression (and its extensions) 
can be used both for aggregated count data and for individual tin1es data. When the 
outcome of interest is a binary event, the output of Poisson regression is the same as the 
output of a parametric survival model called "exponential model". In fact, when the 
event rate is constant over time the distribution of the survival times is an exponential 
function of time, because S(t) = e(- A.* t), i.e. survival probabilities are an exponential 
function of this constant hazard multiplied by time. 
4. Estimating rates from survival data 
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1. Measuring survival data 
The outcome variable of survival analysis is called survival time, although it may be 
applied to the time 'survived' from complete remission to disease relapse or progression 
as equally as to the time from diagnosis to death. Outcome measurement implies precise 
definition of the event of interest and when the period of observation starts and finishes. 
For example, in the fistula data, time was recorded from the creation date of the AV 
access (time zero), and the observation continued for each subject until either a failure 
event occurred (including recurrent thrombosis episodes in multiple AV accesses), the 
study ended, the patient died or was transplanted, or further observation became 
impossible. 
A critical aspect of survival data is that the true time to event remains unknown for some 
individuals who may not have had the event of interest at the end of the follow-up. This 
phenomenon is called censoring and may arise because a patient (a) has not (yet) 
experienced the outcome event by the study close date; (b) is lost to follow-up during the 
study period (e.g., due to transfer to another centre or for consent withdrawal); or (c) 
experiences another (competing) event that makes further follow-up impossible (e.g., 
heart transplantation, a new health problem or even a car accident). Censored 
observations are those who survived at least as long as they remained in the study but for 
whom their actual event-free survival times are not known exactly. Such right-censored 
survival times underestimate the true (but unknown) time to event. lfthe event occurred 
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in all individuals, other methods of analysis would be applicable. However the presence 
of censoring and the distribution of the failure times make survival analysis necessary for 
time-to-event data. 
The analytical tool used to study survival data assumes that if censoring occurs it occurs 
randomly and is unrelated to the reason for failure (independent censoring principle). In 
practical terms, this means that censoring must carry no prognostic infonnation about the 
subsequent survival experience. This must be guaranteed by the study de ign and 
implementation as it cannot be controlled for during the analysis. This "uninformative" 
assumption would be violated if subjects were highly likely to leave the study just prior 
to fai lure or dropout rates between groups were differential. In addition to the 
independent censoring principle, the other key requirements of any risk study also need to 
be satisfied for the validity of survival analysis: follow-up duration based on disease 
severity (sufficient to capture enough events), homogeneous cohort effect on survival 
(similar survival probabilities for subjects recruited early and late in the study), and 
independence of the failure times for standard approaches (absence of correlation in the 
data). 
11. Functions used to study survival data 
Survival data are generally described and modelled in terms of three related functions, 
namely the survivor, the hazard and the cumulative hazard functions. They are different 
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functions of the linear predictor (the regressors and their coefficients) meant to 
summarize the information on the outcome components described above (time zero, end 
date and censor status) in one response variable (11 , 12). The survival probability 
(cumulative urvival probability or survivor function) is the probability (from 1 at t = 0 to 
0 as time goes to infinity) that an individual survives from time zero up to a specified 
future timet (observation end). Survival probabilities at different times provide essential 
summary information from time to event data. Figure 3 shows the estimated primary 
survival probabilities of all 700 A V accesses in the fistula data (left panel). For example, 
a survivor function of0.48 at 3 years informs that 48% of the AV accesses (observed 
from t = 0) are event free at 3 years (risk of0.52 at 3 years). The hazard is the 
instantaneous probability that an individual who is under observation at time t has an 
event at that time. So the hazard is a rate, i.e. a probability over a time interval, though 
very small. Put another way, it gives the instantaneous potential for the event to occur, 
given that the subject has survived up to that instant (conditional rate). In contrast to the 
survivor function, which can only decrease over time, the hazard function can remain 
constant or vary with different shapes over time (Figure 3, right panel). The hazard is 
like a speed, with the risk of failure over time instead of distance covered over time, and 
may assume different values over time (from 0 to +oo) independent of the average value 
calculated in an interval. In the access study the hazard of both primary and (to a lesser 
extent) secondary failure was greater initially, and tended to decrease over time. There is 
a defined relationship between survival and hazard and they are both related to a third 
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quantity called cumulative hazard (Figure 4). The cumulative hazard at t is the integral 
of the hazard (area under the hazard function between times 0 and t). To understand the 
concept it is useful to go back to the speed example. If an A V access faced a hazard rate 
of failure of 0.1 thromboses per hour (a speed of 0.1 mph), then the cumulative hazard is 
such that were that rate to continue for two days (the speed constantly at 0.1 mph) 4.8 
failures were expected to occur ( 4.8 miles travelled) in 2 days. Since an integral is indeed 
just a sum, a cumulative hazard is not unlike the total number of times the A V access 
"would fail" over the interval period (cumulative force of mortality). 
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Kaplan-Meier survival estimate Smoothed hazard estimate 
0 12 24 38 
Months from access cr atlon Months from access creation 
Figure 3: Primary survival data from the access study (3). All 700 A V accesses 
attempted in 535 incident hemodialysis patients are included. The left panel shows the 
overall survival probabilities over time since creation (Kaplan-Meier estimator and 95% 
confidence intervals). The right panel shows the hazard (or instantaneous risk) of failure 
over time (with 95% CI). It can be seen that the hazard declines sharply during the first 
months, and remains lower after one year (fluctuations may be due to sample shrinkage). 
Estimates are less precise (wider confidence bands) as fewer A V accesses remain at risk 
(right portion of each panel). 
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Figure 4: Characteristics and relationship among the hazard function A.(t), the survivor 
function S(t) and the cumulative hazard function H(t). 
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5. Making comparisons: Cox's and Poisson regressions 
To compare hazards, survival functions, or times across groups, there are different 
approaches more or less free from specific distributional assumptions about the hazard 
function (Table 8). Furthermore, some parametric models have an accelerated failure 
time metric, i.e. the estimated coefficients (the co-variate effects) are interpretable as log-
time ratios and some have both the proportional hazard and the log-time interpretation. 
The two interpretations are different. The proportional hazard metric focuses on the 
actual risk process (the hazard function) that causes failure and how the risk changes with 
the value of the covariates in the model. The accelerated failure time metric gives a more 
prominent role to time in the analysis (how the survival time changes with the value of 
the covariates in the model). The measures of effect estimated in the models reported in 
Tables 4 - 7 are hazard ratios (Cox's models) and incidence rate ratios (Poisson 
regression). This means that the estimated coefficients are interpretable as log-risk ratios 
(proportional risk metric). In other words, a hazard ratio of 1.316 (coefficient or log-risk 
ratio = 0.274) means that those referred to the nephrologist within 3 months of dialysis 
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Table 8: Forms of survival analyses 
Form Parameter Example Metrics Meaning Exp(Jl) 
Non-P None KM NA Survival Prob. NA 
Semi-P Effects Cox's M PH Risk change HR 
Parametric Effects I A. Gamma AFT Time change TR 
Log-N AFT Time change TR 
Exponential PH / AFT Tor Rchange HR / TR 
Wei bull PH / AFT TorR change HR / TR 
Legend: Exp(fJ), is the number e to the power of fJ, the estimated value of the coefficient; 
NA: not applicable; PH, proportional hazards; HR, hazard ratio; gamma, log-normal, 
exponential and Wei bull are the names of some parametric regression models; AFT, 
accelerated failure time; TR, time ratio. 
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start experienced a risk 31% greater than those followed for longer (Table 4, Model 1 ). 
The model coefficients represent differences in logs by unit change of each predictor (for 
late referral indicator from 0 to 1). The meaning of the coefficients is interpreted taking 
the exponential. Each exponentiated coefficient represents the ratio of the risk between 
two levels or unit of exposure. If the model is formulated in the so called proportional 
risk metric, differences on the log scale are assumed to be constant and ratios on the 
exponential scale proportional (proportional hazard requirement). These effect measures 
can be estimated with semi- and fully parametric models. 
The Cox's model is by far the most commonly used survival procedure. It is a semi-
parametric model since it formulates the analysis of survival data where no parametric 
form of the hazard function (output) is specified and yet the effects of the covariates 
(inputs) are parameterized (i.e., modelled based on assumptions) to alter the baseline 
hazard function (the hazard for which all covariates are equal to zero). The Cox's model 
makes estimation possible assuming that the covariates multiplicatively shift the baseline 
hazard (Figure 5 and Figure 6). 
Besides the ease of coefficient interpretation, freedom from distributional assumption is 
the greatest advantage of Cox's regression. The cost is a loss of efficiency (precision) 
since the parameters are estimated comparing subjects at the times when failures happen 
to occur whereas parametric models maximize the use of the information in the data. 
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Figure 5: Hazards proportionality (12) : The individual hazard at time t (i. e., at any time 
duringfollow-up) given the exposure "X" is afunction of the baseline hazard (Ao) and 
the hazard ratio (HR) associated with each unit change of the input, i. e. A(t) = Ao(t) times 
HR. This HR is estimated as "exp(fi) ". As the estimated coefficients are constant, and 
constant differences on the log scale correspond to constant ratio on the exponential 
scale, the model assumes proportional hazards (Hazards Proportionality - HP). If more 
inputs are in the model each HR is adjusted for the effect of all the other independent 
variables. 
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Figure 6: Stratified Cox' model (1 2): There can be groups with different baseline hazard 
lo(t), such as race groups (e.g. race A and B). If the effect on survival of race A vs. B is 
not of interest (does not need to be estimated) but requires to be controlled for, a 
stratification variable can be used to specify the model (e.g., with possible values A and 
B). The model contains the same predictors (e.g., gender) but allows the basal risk to 
vary, i.e. A.Ao(t) i- l 8o(t). The difference in the linear predictor ([3) between two groups 
of subjects (e.g., men= 1 and women=O) in terms of hazard (e.g. , for cardiovascular 
event) is still constant (Hazards Proportionality - HP) , and is the same in both strata. 
However, as AAo(t) -:f lno(t), also AA(t) i- A.n(t). 
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Thus it is not surprising that the results of the Cox's models (Table 4 and 5) differed from 
those of Poisson models in terms of significance testing (Table 6 and 7). In fact, Poisson 
regression is a fully parametric model which can be applied also to survival data. What 
should cause alarm about the models in Table 6 and 7 are the coefficient estimates rather 
than the results of hypothesis testing. Indeed, the aspect to be verified is whether the 
observed hazard distribution (Figure 3, right panel) is consistent with the distributional 
assumptions implied by the Poisson model. In the access study the rate of access failure 
was not constant over the entire follow-up time. This violates the distributional 
assumption of the Poisson model and makes the models reported in Table 6 and 7 wrong. 
Thus, the inconsistency of the coefficients points out the inadequacy of a model that 
assumes constant baseline hazard, as the assumption of constant hazard is incorrect for 
these data. The main difference between the Cox's model and the other parametric 
models is that with Cox's regression how rates change with time can be ignored (no 
specific distribution of the baseline hazard is specified), while with all parametric models 
this must be taken into account. Some parametric models (such as the exponential and 
the Weibull models) are proportional hazards models. This implies that the log-relative 
hazard has the tandard interpretation, i.e. the exponentiated coefficient is the hazard ratio 
for one unit change in the predictor. The direct comparability to Cox's regression is 
probably the most appealing feature of this class of models. In fact, when engaging a 
parametric estimation it is prudent to compare the estimated coefficients to those from a 
Cox's model fit, to verify that they are roughly similar. If they prove not to be similar, 
then there is evidence ofmis-parameterization of the underlying baseline hazard. When 
the chosen parametric model is correct, or the effect of time is controlled for, coefficient 
estimates from parametric models are close to those of Cox's regression (Table 9). In the 
example, the follow-up time was divided into pieces within which the hazard appeared to 
be approximately constant (0 - 3, 3 - 6, 6 - 12, 12 - 20, 20 - 30 and > 30 months). 
However, sometimes rates vary so quickly with time that it would be necessary to split 
the follow-up into too many pieces, or it would be difficult to decide how to split the 
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Table 9: Models of the primmy failure of the l s1 A V access in the access study (N = 51 3) 
Poisson model adjusted for the effect of time bands (0-3, 3-6, 6-12, 12-20, 20-30 & > 30 
months) 
Co-variate IRR P>lzl 95% Confidence Interval 
LR 1.360 0.070 (0.975 to 1.896) 
HF 1.146 0.525 (0. 753 to 1. 745) 
HXL 2.007 0.056 (0.981 to4.107) 
VASC 1.377 0.025 (1.040 to 1.822) 
Cox's model (no band adjustment) 
Co-variate HR P>lzl 95% Confidence Interval 
LR 1.328 0.095 (0.952 to 1.854) 
HF 1.142 0.537 (0. 749 to I. 739) 
HXL 1.902 0.078 (0.929 to 3.890) 
VASC 1.359 0.032 (1.027 to 1.798) 
Legend: IRR = incidence rate ratio; P>izi two sided P value of the Wald test on the 
coefficients; LR = late referral (referral to the nephrologist less than 3 months of the 
dialysis start); HF = history of heart failure; HXL interaction term between HF and LR; 
and VASC: presence of vascular disease (previous clinically documented coronary, 
cerebral or peripheral events). Subjects receiving an AV graft were excluded from both 
models (N = 22). 
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data. With Cox's regression it is not necessary to split the data into time pieces because 
Cox's regression implicitly controls for time continuously. Both methods assume that the 
risk ratios are constant over the entire follow-up. In Poisson regression the effect is the 
ratio of two incidence rates, each constant within the time band whose effect is controlled 
for in the model. In the Cox's model the hazard ratios (HR) estimate the true risk ratios 
(RR) of instantaneous event rates. In fact, as with rates, HR is an instantaneous RR, the 
limiting value for the RR as time approaches zero. As time approaches 0, the risks also 
approach 0. However, the value ofHR is different from zero and approaches that of the 
true RR. In survival analysis, the incidence rate ratio is the limiting value for the RR as 
time approaches 0. Poisson regression models rates, which are assumed to be low and 
constant with variance equal to the mean. Often complex survival data can be aggregated 
and Poisson regression and other generalized linear models can be used provided that the 
above assumptions are satisfied. 
6. Parametric survival models 
Linear regression, logistic regression and Poisson regression are examples of parametric 
models. With these models the outcome is assumed to follow a distribution from a 
certain family (normal, binomial, Poisson) with unknown parameters. For example, if 
one distribution has some parameters (e.g., mean systolic blood pressure 130 with SD 20 
mmHg) and another distribution has different parameter values (e.g., 110 ± 10), the two 
distributions belong to the same family (nom1al) but they are different di tributions. In 
parametric regression models data are typically used to estimate the value of the 
unknown parameters that fully specify the chosen distribution. The exponential and the 
Weibull models are two parametric proportional hazards models. As with the Cox's 
model they have the following structure A.(t) = 1-o(t)e(Xp), which mean that the hazard at 
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any time t during the observation period depends on the baseline hazard A.(t) times the 
hazard ratios HR = e(Xp). The term "parametric" means that in addition to the log-
hazard ratios (betas) they produce direct estimates of the baseline hazard A.o(t). In the 
Cox's model this baseline hazard is left un-parameterized and through conditioning on 
failure times the hazard ratios are obtained anywa/. Parametric models estimate 
additional parameters defining the shape of the baseline hazard. These include an 
intercept and the so called "ancillary parameters". These additional parameters are the 
coefficients of the hazard function implied by the model. From these parameter it is 
possible to obtain the predicted baseline hazard function and the other related functions, 
i.e. the survivor and the cumulative hazard functions (Figures 4 and 7). Since the 
exponential and the W eibull models have both the proportional hazard and the 
accelerated failure time interpretation (Table 8), these two models will be used to fit the 
A V access study data and compare the two interpretations. Parametric models need not 
be PH models. Some have only the proportional hazard formulation (Gompertz) and 
others the accelerated failure time fonnulation (log-normal, log-logistic, and gamma). 
Some of these models are naturally non-proportional (log-nonnal) and some have several 
ancillary parameters possessing a highly flexible hazard function which allows for a large 
number of possible shapes (gamma). However, this is beyond the scope of the present 
work and will not be discussed further. 
Although the baseline hazard and survival functions are not estimated with Cox's regression, these can 
be derived generalizing the Kaplan-Meier method and using the estimated effects. However, baseline 
hazard est imation is not necessary in Cox's regression because in the computations of the effects {I-I R) 
the baseline hazard cancels out. 
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Table 10 shows the primary survival of the first AV access (fistulae only) from the access 
study data fitting the Cox's, the exponential and the Weibull models in the (log) 
proportional hazard metric. Once the effect of time has been controlled for, the 
exponential model provides results similar to those of the Cox's models (Table 10) at the 
cost of estimating 6 additional parameters: the effects of each of the 5 time bands relative 
to the first band (month 0 to 3), and the intercept "a", which indicates that the baseline 
hazard is constant over time. Actually, splitting time in several pieces may even improve 
the results but would make the model more complex. The exponential model is useful to 
check "non-parametrically" the validity of any parametric form the researcher whishes to 
use. This piece-wise exponential model was used to identify the chosen time band 
categories along with the observed data from Figure 3. The exponential model can be 
used even if the overall hazard varies with time, provided that the process under study is 
understood and taken into account. For example, it is reasonable to believe that the 
hazard of fistula thrombosis is greater in the first days after surgery than later on. Based 
on the intercept and the effect of time (how the hazard changes with time) it is possible to 
predict the instantaneous baseline hazard within each time band, i.e. the instantaneous 
risk for failure in those not referred in a timely manner to the nephrologist and without 
cardiovascular disease. The effect of time is to alter the baseline hazard by an amount 
estimated by the coefficient associated with each time band, and the model is valid 
provided that the baseline hazard controlled for time remains constant within that time 
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Table 10: Models of the primary failure of the first A V fistula (N = 513) 
Cox 's model (see the HR in Table 4, model2) 
Co-variate log-HR P>lzl 95% Confidence Interval 
LR 0.410 0.006 (0.1 16 to 0. 705) 
CVD 0.397 0.004 (0.127 to 0.667) 
Exponential model adjusted/or time bands (0-3, 3-6, 6-12, 12-20, 20-30 & > 30 months) 
Co-variate log-HR P>lzl 95% Confidence Interval 
LR 0.444 0.003 (0. 150 to 0.738) 
CVD 0.415 0.003 
a - 2.702 <.001 
Weibull model (no band adjustment) 
Co-variate log-HR P>lzl 
LR 0.429 0.004 
CVD 0.406 0.003 
a 
p 
- 2.276 
- 0.797 
<.001 
<.001 
(0.145 to 0.685) 
(- 2.954 to- 2.450) 
95% Confidence Interval 
(0.135 to 0.724) 
(0.136 to 0.676) 
(- 2.545 to- 2.007) 
(- 0.916 to - 0.678) 
Weibull model with band adjustment (effect of the time bands 3-30 & > 30 v 0-3 months) 
Co-variate log-HR P>lzl 95% Confidence Interval 
LR 0.414 0.006 (0. 119 to 0. 708) 
CVD 0.400 
a - 2.235 
p - 0.616 
0.004 
<.001 
<.001 
(0. 130 to 0.670) 
(- 2.503 to - 1.968) 
(- 0.783 to - 0.449) 
Legend = log-HR: log-hazard ratio (beta coefficients); P>izi two sided P value of the 
Wald test on the betas (log-HR),· LR = nephrology referral < 3 months of dialysis; CVD 
= history of heart failure and I or presence of vascular disease (previous clinically 
documented coronary, cerebral or peripheral events). The coefficients "a" and "p" are 
respectively the intercept and the ancillary (log) parameters. 
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band. From the baseline hazard (controlled for time) and the coefficients of the 
covariates in the model it is possible to estimate the hazard of those referred late (baseline 
hazard times the HR of late referral) or with cardiovascular disease (baseline hazard 
times the HR of cardiovascular disease) or both (baseline hazard times the HR of late 
referral times the HR of cardiovascular disease - multiplicative model). 
Also the Weibull model provides results that seem close to those of the Cox's model, with 
the additional advantage of estimating fewer parameters than the exponential model to do 
the same job (Table 10). In fact the second new parameter "p" is the ancillary parameter 
of the Weibull model (Figure 7). This parameter detennines the fonn of the baseline 
hazard, i.e. how the hazard changes over time. This is why the ancillary parameter is 
called the shape parameter as opposed to the other parameters (intercept and the co-
variate coefficients) which are called scale parameters as they alter the level of the 
hazard proportionally, i.e. independent of time. In the Weibull model of the fistula data 
the hazard is monotonically decreasing as (log) p < 0 (it would be monotonically 
increasing ifp > 0 and flat ifp = 0, the model reducing to the exponential case). As with 
the Cox's model the baseline hazard is altered multiplicatively by the effect of the 
covariates in both the exponential and Weibull regression models (i.e. these baseline 
hazards increase by approximately exp(0.4) = 50% in presence of any cardiovascular 
disease or if the patient is referred late). The ancillary parameter canal o be modelled as 
a function of some (or several) co-variates, allowing each risk group to have its own 
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With p > I 
Figure 7: Relationship between three parametrically specified hazards and the 
corresponding survival probabilities. The first )..(t) is a constant hazard rate over time 
(e.g., a constant speed); the following are the decreasing and increasing hazard rates 
based on a Weibull model (e.g., decreasing and increasing speed over time). These 
curves are illustrative examples and other shapes are possible. As opposed to the Cox's 
model where the baseline hazard A.o(t) was simply left un-parameterized and the 
coefficient estimates were obtained anyway through conditioning on failure times, in 
parametric models afunctional form ofA.o(t) is specified through 1 (e.g. the intercept "a " 
of the exponential and Weibull models) or additional parameters (e.g. the ancillary 
parameter "p" of the Weibull model). 
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hazard shape. For example, the hazard might decrease more slowly (p < 1 but closer to 
1 ), or more quickly (p < l but closer to 0), in subjects with vascular disease than in those 
without vascular disease, or might even increase instead (p > 1 as opposed to < 1). 
Including presence of vascular di ease in the co-variate list only assumes that this co-
variate has an effect on the scale of the hazard (HR) but that the shape of the hazard (p) is 
the same for both its levels (as was the case in these data for all covariates). It is possible 
to assume that the shape of the hazard (p) changes with the level of a co-variate and not 
the scale (HR). It s also possible to assume that both the scale and the shape of the 
hazard are affected as the co-variate values change. 
Table 11 shows the primary observed event rates of the first AV fistula and the hazards 
predicted by the exponential and Weibull models within each time band. It can be seen 
that despite its parsimony, the Weibull model does not seem to work well in predicting 
the risk at the beginning and at the very end of the observation times. The predictions of 
the Weibull model improve when the effect of two time pieces are controlled for (i.e. if 
the model allows additional changes of the hazard over time). However, it should be 
noted that the table reports averages which reflect the implications of the exponential 
model (as this implies a constant hazard within each time band) but not those of the 
Weibull model which has an ancillary parameter. In fact the hazard decrea es (or 
increases) monotonically according to the Weibull model by an amount estimated by this 
shape parameter. In fact according to the second Weibull model in Table 10, the hazard 
50 
Table 11: Observed primary failure rates of the first A V fistula and hazards predicted by 
the exponential and the Weibu/1 models (Table 10). The exponential model appears to 
work better than the Wei bull models. The predictions of the Weibu/1 improve when the 
effects of two time pieces are controlled for. 
Time band Observed Exponential Weibull (1) Weibull (2) 
0 to 3 months 0.0931 0.0957 0.0708 0.0807 
3 to 6 months 0.0248 0.0250 0.0242 0.0209 
6 to 12 months 0.0155 0.0156 0.0165 0.0152 
12 to 20 months 0.0134 0.0134 0.0123 0.0119 
20 to 30 months 0.0134 0.0104 0.0098 0.0099 
> 30 months 0.0053 0.0053 0.0077 0.0053 
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Table 12: Parametric models of the primary failure of the first A V fistula in the access 
study (N = 513) formulated in the accelerated failure time metric. 
Exponential model adjusted for the effect of the time bands (0-3, 3-6, 6-12, 12-20, 20-30 
& > 30 months) 
Co-variate log-TR 
LR - 0.444 
CVD - 0.415 
a 2.702 
95% Conf. Int. TR 
- 0.738 to - 0.150 0.641 
- 0.685 to - 0.145 0.660 
2.954 to 2.450 
95% Conf. Int. 
0.4 78 to 0.861 
0.504 to 0.864 
Weibull model with band adjustment (effect of the time bands 3-30 &> 30 v 0-3 months) 
Co-variate log-TR 95% Conf. Int. TR 95% Conf. Int. 
LR - 0.766 - 1.321 to - 0.2 10 0.465 0.266 to 0.810 
CVD - 0.741 - 1.253 to - 0.228 0.476 0.285 to 0. 795 
a 4.138 3.435 to 4.841 
p - 0.6 15 - 0.783 to - 0.448 
Legend: log-TR = log-time ratio (coefficients); TR =exponentiated coefficient (time 
ratio); LR = late referral (referral to the nephrologist < 3 months of dialysis); CVD = 
history of heart failure and I or presence of vascular disease (previous clinically 
documented coronary, cerebral or peripheral events). The coefficients "a" and "p" are 
respectively the intercept and the ancillary (log) parameters. 
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Table 13: Estimated median times to failure (in months) from the models in Table 12. 
Exponential Weibull 
LR- /CVD - 53.53 (10.33 to 164.66) 74.91 (31.80 to 172.82) 
LR- /CVD+ 33.58 (6.82 to 108.82) 34.90 (15.16 to 82.36) 
LR+/CVD - 30.46 (6.63 to 105.64) 32.66 ( 14.78 to 80.34) 
LR+/CVD + 17.89 (4.37 to 69.75) 14.33 (7.04 to 38.29) 
Legend: LR = late referral absent (-) or present(+); CVD =cardiovascular disease 
absent(- ) or present(+). Each cell reports the mean, the minimum and the maximum 
estimated categaty values. 
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decreases quickly during the first month, from 0.28 at day 1 to 0.11 after 1 week and to 
0.06 at the end of the third week. This may explain why the coefficient estimates from 
the Weibull model are closer to those of the Cox's model than those of the exponential 
model (Table 10). 
Table 12 shows the results of the same exponential and Weibull models controlled for 
time in the accelerated failure time formulation. When these models are expressed in this 
metric, the coefficients are log-time ratios. In other words, the exponentiated coefficients 
are interpretable as time ratios, i.e. the ratio of the predicted time to failure associated 
with a level of the regressor to the predicted time of the previous level. The underlying 
assumption for AFT models is that the effects of the covariates are multiplicative 
(proportional) with respect to survival times (time comparison) as opposed to PH models 
where the effects of the covariates is multiplicative with respect to hazards (hazard 
comparison). Mean and median survival times (and measures of dispersion) can be 
predicted using this fonnulation (Table 13). 
The word "accelerated" is used to describe these models because they follow the 
parameterization2 log(t) =- xp + log('r). This last term log(r) has a distribution defined 
by the model. After taking the exponential r = e(XP)*t, where e(Xp) is the TR. Its 
reciprocal e(- XP) is the acceleration parameter (AP) which estimates how the "speed of 
2 The AFT formulation is reported as log(t) = xp + log('r) by some, where Xp is the log{AP) = - log(TR). 
After taking the exponential T = e {log(t) ····· log(AP)} and r = t! AP = t*TR (Figure 8). 
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the process" changes. In fact, if AP = 1 (TR = 1) then 't = t and time passes at its 
"normal" rate (the covariates do not have any effect); if AP > 1 then time passes more 
quickly for the subject (time is accelerated) and the failure event is expected to occur 
sooner (TR < 1); and if AP < 1 then time passes more slowly (time is decelerated) and 
failure is expected to occur later (TR > 1). These models are called "accelerated" 
because the effect of a covariate measured in time units increases with time. For 
example, if the p coefficient of a covariate xis - 0.75 (TR = e(- 0.75) = 0.472 and AP = 
1/TR = 2.117), one unit increase in x would speed up the process by a factor 2.117 
resulting in a decrease in the expected value of log(t) by 0. 75. ln fact, the effect of the 
covariate would anticipate the occurrence of failure to 't = e(log(1) - 0.75) = 0.472 at t = 
1; to • = e(log(5) - 0.75) = 2.361 at t = 5; and to 't = e(log(lO) - 0.75) = 4.723 at t = 10. 
Of note the predicted times to failure per unit change in the covariate x are "proportional" 
as AP is constant ( 110.4 72 = 5/2.361 = 10/4.723 = 2.117 = e[- xp]). However, at larger 
times greater absolute anticipations are expected when the coefficient P < 0 (TR < 1 and 
AP > 1) and longer absolute delays are expected when p > 0 (TR > 1 and AP < 1). This 
is why the marginal effect ofx "accelerates" (or "decelerates") as time goes by. Figure 8 
shows predicted survival times overt for different values of AP (page 57). 
The coefficient p can also be viewed as an accelerating factor stretching or contracting 
time given a certain value of the survival probability. For example, dogs are said to grow 
older seven times faster than humans. The coefficient of the covariate "being dog as 
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opposed to human" in an AFT model would be Po = log( 1 /7) = - 1 .94591. The TR of 
dogs versus humans would be e(/)0) = 0.1428571 (1/7). In terms of probability of 
surviving "past some age", this means that a 10 year old dog would have the same 
survival probability as a 70 year old human. In fact, according to the AFT assumption at 
any value of the survival probability S(t) the ratio of times (TR) is constant, i.e. S0 ( 1 0) = 
SH(TR * 1 0) = SH(70) and SH(70) = S0 (AP*70) = SH( 1 0). In terms of time to = e(log(70) -
1.94591) = 10. In other words, the life-span of dogs is contracted (that of humans is 
stretched out) by a quantity estimated by the model coefficient p formulated in the AFT 
metric. Figure 9 shows predicted survival probabilities overt for different values of TR 
(page 58). 
An obvious question at the end of this brief review of standard analytical methods for risk 
estimation in longitudinal studies is: "Why should we bother with parametric models if 
the Cox's model remains the "safest" estimation method or "gold standard" if you prefer? 
Actually Cox's regression was used for the analysis of the Italian access data ( 1 - 4 ). 
However, often researchers are unaware of methods for the analysis of repeated events 
and fully parametric estimation procedures. In some circumstances these methods may 
be more appropriate. There are at least 4 aspects that should be considered when one is 
engaged in the analysis of risk data from longitudinal studies: 1) The parametric 
estimation scheme is more efficient (more precise) because it makes better use of the 
infonnation in the data using probabilities that depict what occurs over the whole 
56 
observation time, and not only at the times when events happen to occur; 2) Parametric 
estimation methods are appropriate when one has an idea of what the baseline hazard 
looks like (such as in the case of AV access failure), and wants to impose that idea in 
order to obtain the most efficient estimate of the parameters and predict the baseline 
hazard subject to that constraint; 3) Parametric models are useful if one is interested not 
only in the hazard ratios but also in predicting the time to failure which requires some 
sort of parametric assumption; finally 4) Parametric models offer some advantages to 
study correlated data in terms of frailty. In fact the parametric form of the baseline 
hazard that parametric models posit allows easier description of the shared frailty (within 
individual or group dependencies). In addition, in the context of parametric models, this 
shared frailty can be contrasted with the latent individual un-shared frailty (over-
dispersion or heterogeneity) which cannot be modelled with Cox's regression. These 
issues will be discussed in the next sections. 
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Figure 8: Predicted times to event (r) as a function of the acceleration parameter AP (y) 
and the follow-up timet. AP is the reciprocal of the time ratio (TR = e[X/3]), i.e. y = e(-
X/3). Time is stretched out to greater values when y < I (e.g., if non smokers have a 
survival time twice as long as smokers or a TR = 2, then y = e(- log[TR]) = 0.5). Time is 
contracted when y > 1 (e.g., sicker patients die sooner than healthy individuals, and pets 
grow older faster than humans). 
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Figure 9: Survival probability S(t) as a function of the reciprocal of the acceleration 
parameter AP (y) or time ratio TR (e[XfJ) = 1/y), the hazard A. (held at 0.01), and the 
follow-up time t. The effect of the covariate xis to extend ( 1/y > 1) or contract ( 1/y < 1) 
the expected time to failure. At the same expected survival probability (in the example * 
= 0.135) the expected time to failure is multiplicatively affected by 1 ly. 
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3) Chapter 3: Methods for the analysis of correlated events 
61 
Chapter overview 
Chapter 3 introduces definitions of and analytical approaches to correlated data. 
Statistical methods for correlated data can be distinguished into two major families: 
random effects models and pragmatic methods. Random effects modelling relies upon 
assumptions about the distribution of the extra-variability in the data once the fixed fixed 
effects have been estimated. Pragmatic methods correct the variance of the fixed effects 
without requiring extra-assumption to be satisfied. Pros and cons of each method is 
discussed at the end of the chapter. 
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1. Analysis choice and implications 
Analysis of repeated AV access failure is possible considering more than one event per 
subject. As opposed to the analysis of the first event that occurs which ignores additional 
information in the data, analyses of event rates including multiple events per person have 
the potential to provide measures of disease burden in a population often more relevant 
and clinically interpretable. For example, in the A V access study the question is "Does 
late referral to the nephrologist impact the risk of failure of the first and further A V 
accesses?" as opposed to "Does late referral to the nephrologist impact the risk of failure 
of the first A V fistula?". Separate standard models of the fate of the first, second and 
subsequent accesses per person represent another option. However, the analysis power of 
the second, third and subsequent A V accesses would become smaller and smaller as 
fewer and fewer people have further A V accesses after the first. Multiple failure times 
analysis still allows testing whether the risk varies by access number while using all the 
information in the data. 
Considering multiple A V accesses per patient or different possible events in each 
individual such as dialysis and death requires the recognition that some subject may be 
especially likely to experience recurrent or multiple events, or become more prone to 
further events during a recurrent process or to competing events of different type. This 
tendency is called frailty and generates correlation in the data threatening the validity of 
traditional analytical tools. Alternative methods make use of all information in the data 
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while accounting for the lack of independence of the event counts or failure times. 
2. Sources of correlation 
Correlation in the occurrence and timing of repeated or multiple events may ensue when 
individuals experiencing a single event belong to group or clusters, when a subject 
experiences some event more than once due to a recurrent event process, or when a 
subject experiences different events. This correlation may result from differences in the 
general tendency to fail across individuals and varying tendency to fail further once the 
recurrence process has started (Figure 1 0). Heterogeneity across subjects (also called un-
sharedfrailty) may be due to unknown, unmeasured, or un-measurable effects (different 
lifestyles, genetic traits, environmental factors and experiences) which influence the 
likelihood to succumb to disease. As a result, some individuals are more (and others less) 
prone to disease, experiencing their first, second, third, etc., recurrence more (less) 
quickly than others. Event dependence within a subject emerges when the threshold for 
further events changes once previous events have occurred (e.g., the baseline risk of 
failure of the second and third access is progressively higher or lower than that of the first 
access). Further events become more or less likely according to whether the process 
induces a biological weakening or strengthening of the organism and whether the subject 
is more or less frail (shared frailty). In either case the risk for an event is a function of 
previous occurrences. Medical research and clinical experience suggest that both 
individual un-shared tendencies and varying shared susceptibility to fail during the 
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This heterogeneity can be incorporated 
into the model as random effect term 
A.(tiX) = A.o(t) exp(X~ + frailty) 
'~ ... __ .... ,-'"/ 
This shift in the baseline hazard can be 
controlled stratifying the model 
A.(tiX) = "-on(t) exp(Xj3) 
Figure 10: Sources of correlation within risk data (survival approach). Unknown (or 
unmeasured) cluster I individual/eve/ factors can be responsible for heterogeneity across 
groups (with consequent different baseline group risk - Aoa. A.ob. A.oc. etc.) and within 
group dependence of the failure events (varying baseline risk within cluster I subject 
during the recurrent or multiple failure process - A.o1. Ao2, AoJ, etc.). Heterogeneity across 
cluster I individuals can be modelled as a random effect term. Event dependencies can 
be controlled for by stratification. 
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recurrent process are likely to be the rule, rather than the exception, in the study of 
multiple events and that each may enhance the effect of the other (22 - 25). 
It has been previously mentioned that independence of the failure times is a key 
requirement for survival analysis to be valid. Also Poisson regression assumes that the 
events are independent. Any correlation among events violates the assumption that the 
timing of events, or the event counts, is independent. This has two important 
consequences: the regression model is both biased and inefficient in a typical repeated 
events context. Variations of survival and count models, namely variance-corrected and 
random effects models have been proposed to account for, and possibly correct, the 
biasing effect due to the correlation among event times or counts. 
3. Random effects modelling 
To understand the philosophy of random effects models it is useful to use the analysis of 
variance approach to the general linear model. Figure 11 shows the change in left 
ventricular mass index as a function of study time and two blood pressure targets 
(standard or rigorous regimen). The bell curves represent the distribution of the response 
values measured at yearly intervals. Repeated measurements within the same subject 
make it possible to identify random individual deviations from the treatment group 
average. Put simply, around the line of the average response to treatment there are other 
lines each with its intercept and slope. Random effects are sources of variability in the 
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baseline) 
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Figure 11: Graphical representation of fixed and random effects. Fixed effects are 
differences in the response - left ventricular mass index (L VMI) by exposure levels -
blood pressure targets (continuous curves and lines). Random factors are responsible 
for the deviations from the averagefcxed effects (2 subjects are indicated for simplicity 
with dashed curves in only one treatment group). Random effects (dashed lines) can 
affect either or both the intercept and the slope of the line defining the input-output 
relationship. In other words, independent of the fixed effects, different subjects (in both 
treatment groups) may have different average values of the response either or both at any 
given value of the exposure (random intercept - vertical distance between lines) and by 
level of exposure (random slope - rate of average change). 
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intercept and slope of the group lines (fixed effects) that can be taken into account 
because they are due to subjects. In other words, these random or individual effects 
account for the variation in the response that the predictors of interest fail to explain but 
can be controlled for. Although not as easy to represent graphically, these random effects 
exist also in other generalized linear models (including those for counts) and survival 
models (13). 
More generally, it is always useful to look at the study outcome variability as a mixture 
of different components. The regression coefficients of the model covariates estimate the 
"explained variability" of the response (systematic component). These are called fixed 
effects, because they are associated with fixed factors (or continuous inputs) whose levels 
of interest are actually measured or measurable. Fixed effects are unknown constant 
population parameters (e.g., the "true effect" of blood pressure target on left ventricular 
mass). The levels of interest ofthe fixed covariates are known or chosen by design (e.g., 
gender or exposure levels, or categories of a continuous covariate such as blood pressure 
targets). However, other covariates are often measured in some studies. They are called 
random classification variables because their levels can be thought of as being 'random I y 
sampled from a population of levels ' , such as individuals A, B, C in repeated I 
longitudinal designs, Drs A, B, C, or hospitals A, B, C and so on in clustered studies. All 
possible levels of these random factors are not present in a single study, but researchers 
still intend to make inferences about the entire "population of levels". In the above 
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example, study participants are random factors. To distinguish between random and 
fixed factors, it is useful to answer the following question: "Were the study to be repeated 
would the same groups I levels be used again?" If yes (e.g., gender, smoking, quality of 
pre-dialysis care, treatment A v B, age groups): this implies fixed effects. If not (e.g., 
centres, regions, subjects) it implies random effects. However, the same variable may be 
treated as fixed factor in some studies, and as a random variable in others, depending on 
the study question (e.g. , health policy effects). 
Of course all models have a random component that represents what remains to be 
explained once the model has been fitted (11, 12). However, a model containing a 
random effect splits its random part into two layers, the variation explained by the 
random factors and what remains unexplained by the combination of fixed and random 
factors (13). Random effects are unobserved random changes of the response by levels 
of the random factors or deviations from the relationship described by the fixed factors. 
For example, suppose that an outcome such as peripheral blood flow is measured twice in 
the same subject before an experiment is undertaken (Figure 12). Response values in the 
same subject tend to be closer to each other than values obtained from different 
individuals. Consequently, two error components exist rather than one. One is due to 
subject (between subject variation) and it is the random effect shared within individual 
but varying across them (heterogeneity). The other is due to the measurement occasion 
nested withjn subject (within subject variation). Within subject residuals are closer 
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Figure 12: Between (B) vs. Within (W) Subject (j) Correlation and Variance 
Components: Blood flow rate values recorded on two occasions in the same subject are 
correlated as they (1) tend to lie on the same side of the overall mean (linear predictor, 
LP); and (2) be closer to each other than those taken on different individuals (within 
subject variability< between subject variability). The response value (y;) of subject (j) 
in occasion (i) equals LP plus an error term((;). This includes two components: the 
variability due to subject ")" (random effect t:J equal to the difference between the subject 
mean (/.1.) and LP); and the variability due to measurement on occasion "i" (effect of 
occasion €ij nested in subject equal to the difference between fiJ and each response 
measured on), y;). Usually it is assumed that both these components are normally 
distributed(- N) with mean zero and some non-zero variance (1/1 and B). In linear 
random intercept models the intra-class correlation coefficient p estimates the outcome 
correlation as the proportion of the total variance explained by the variance (B) of the 
random effect (() . 
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together than between subject residuals due to "shared characteristics". The variability 
due to measurement can be estimated when more than one measurement is performed in 
the same subject, although it exists independent of the number of measurements 
performed. A random effect model estimates both these variance components. When the 
variance of the random effect is significantly different from zero, the null hypothesis of 
absence of correlation in the data is rejected. The proportion of the total variance due to 
subject estimates the correlation in the data, and the accuracy of the measurement tooe. 
The heterogeneity among clusters I subjects and the dependencies within cluster I subject 
are incorporated into the estimated portion of the model by making assumptions about the 
distribution of the resulting random effect (13). As a result, under random effects models 
the outcome response (event times or counts) are assumed to be independent conditional 
on the patient's underlying frailty and inference can be made in the standard fashion. 
Random effects models estimate the variance of this latent effect. When this variance is 
significantly different from zero, the model supports the hypothesis of a significant 
heterogeneity I dependencies in the data. 
4. Robust variance method 
Robust variance or variance-corrected models represent another way to deal with the 
3 When one observation per subject has been collected, un-shared random effects can be modelled using 
parametric models. In such models the frailty term is used to correct the over (under) dispersion 
implied by the chosen distribution. When more than one record per individual is available or subjects 
belong to clusters, it is also possible to predict the frailty value for each individual or cluster using 
shared frailty models. 
71 
problems produced by heterogeneity across individuals and failure-time or count 
dependencies. These methods do not incorporate any random effect into the estimates 
themselves but were developed to account for the lack of independence by using "robust" 
standard errors (also known as "sandwich estimator" from the matrix algebra). This 
method corrects the variance of the coefficient estimates (the random part of the model) 
for the correlation in the data by incorporating the dependencies in the process of 
computations. This is done by removing one cluster at a time, and providing an honest 
estimate for correlated data whenever the observations left out at any step are 
independent of the observations left in (22, 23). The standard errors of the coefficients 
are usually (but not always) larger, depending on the sign of the correlation in the data. 
Put simply, the statistical testing is more conservative (the confidence intervals larger) as 
compared to the corresponding generalized linear model applied to the same data as 
though each observation was independent (independent correlation structure). This 
empirical method is called robust because the variance estimation is consistent, even if 
the chosen correlation structure is incorrect (robustness to mis-specifications). This 
robust or corrected variance method can be used both for count and survival models, and 
both for semi-parametric and parametric models. 
Although it is possible to run a standard Poisson model using robust standard errors, a 
popular approach to the analysis of correlated count data is represented by Generalized 
Estimating Equations (GEE). GEE are a class of analytical methods which represents the 
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extensions of standard generalized linear models for repeated I multiple measures (13). 
GEE have the same structure as standard regression models, i.e. a systematic component 
and a random component without specification of any additional random layer (random 
effect). The estimation method of GEE requires the specification of a working 
correlation for the observed responses to obtain unbiased estimates of the coefficients and 
their variances (Table 14). As a result, the standard errors of the GEE coefficients are 
corrected assuming that one or more correlation coefficients (parameters) describe the 
association of pairs of different responses from the same subject or cluster. Which 
structure best describes the real data correlation is not always obvious, although the 
research design may help decide. However, GEE analysis requires only a rough estimate 
of this structure to get started. The final parameter estimates (fixed effects, their standard 
errors, and the p correlation coefficients) are not usually dependent on the accuracy of the 
initial assumptions about the correlation matrix. In fact they are consistent (i.e., converge 
to the true value) as the number of clusters I subjects increases even if the initial structure 
is incorrectly specified, unless the fraction of missing data is large or they are not missing 
at random4 . Although the correlation structure is not necessarily the same for all clusters 
I subjects, GEE assume one set of p parameters common to all clusters I subjects to avoid 
estimating too many parameters. Given the importance of the chosen correlation 
4 Data are said to be missing at random (MAR) if, conditional on the observed data, the missingness is 
independent of the unobserved measurements (as opposed to data not missing at random, MNAR). 
Maximum likelihood estimation still retains its desirable properties (validity, consistency, efficiency) 
provided that data are MAR. For GEE to be valid this may not be enough and data need to be missing 
completely at random (MCAR), i.e. the missingness must be independent of both unobserved (missing 
value of the response) and observed data (previous response data and covariates values). 
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Table 14: Examples of correlation structures used in GEE: Each panel represents a 
correlation matrix between any two of 4 possible observations in the same subject taken 
at time 1, 2, 3, 4 (or in subject 1, 2, 3, 4 of the same cluster). Each matrix has a value of 
1 along the main diagonal (as each measure correlates perfectly with itself) and some 
non-1 value off the diagonal. in the absence of correlation (independent errors) the 
correlation structure is independent (identity matrix); it is exchangeable if there is only 
one parameter p for any pair of measurements (e.g., in a cross-sectional study the order 
of measurement is arbitrary and it may be assumed that any two responses within a 
cluster have the same correlation); unstructured if there are n*(n-1)12 different 
parameters p (e.g., if it is assumed that there are as many p parameters as there are 
paired combinations ofn measurements); autoregressive if there is only one praised to 
the power of the absolute difference between the response times (e.g., in longitudinal 
designs it is reasonable to assumed that the correlation is greater for observations taken 
closer in time than farther apart as the order of measurement is not arbitrary). 
T1 T2 T3 T4 Tl T2 T3 T4 
Tl 0 0 0 p p p 
T2 0 0 0 p p p 
T3 0 0 0 p p 1 p 
T4 0 0 0 1 p p p 
Independent Exchangeable 
T1 T2 T3 T4 Tl T2 T3 T4 
T1 1 Pt2 Pt3 Pt4 1 p p2 p3 
T2 P21 P23 P24 p 1 p p2 
T3 P3t P32 1 P34 p2 p 1 p 
T4 P4t P42 P43 1 p3 p2 p 
Independent Exchangeable 
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structure, the possibility of mis-specification in real life situations and, most of all, the 
possibility that data may not be missing completely at random, robust standard errors are 
usually recommended with GEE. Examples of random effects and GEE Poisson 
modelling of the AV access data will be presented in chapter 6. 
The survival counter part of such "robust" approaches is represented by the family of 
robust variance methods. These survival techniques have been developed as extensions 
of the standard Cox's model. Variations within the variance corrected survival models 
are based on the definition of the risk sets (when the risk starts and ends for each subject) 
and whether event specific baseline risk is allowed by stratification. These models will 
be presented separately in their semi-parametric (chapter 5) and parametric fonnulation 
(chapter 6) with examples. 
5. Method choice 
The choice of the analytical tool to correct for the correlation in the data can be guided by 
different considerations. 
As opposed to random effects models for counts, GEE are based on only one level of 
clustering, are not designed for inferences about the covariance structure (the working 
correlation structure is formulated with no distributional assumptions) and do not give 
predicted response values for each cluster. Using random effects models involves 
making extra assumptions, but gives more efficient estimates, and allows estimating 
75 
contributions to variability from different sources, including multilevel correlations. 
finally, GEE are marginal models as they assume a model holding over all clusters 
(population average). Therefore, the coefficients represent the average change in the 
response over the entire population for a unit change in the predictor. Random models 
are conditional models in that they assume a model specific to each cluster I subject. 
Therefore, the coefficients represent the average change in the response for each cluster I 
individual, given a unit change in the predictor. Although population effects can be 
derived averaging cluster effects, conditional models are most useful when the objective 
is to make inferences about clusters I individuals rather than the population. 
Similar considerations apply to survival analysis. In survival analysis stratification 
represents an additional advantage of variance corrected (robust) survival methods versus 
GEE for counts. Parametric survival models can fom1ally distinguish between un-shared 
and shared frailty, and estimate the so called "frailty effect" (chapter 6). 
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4) Chapter 4: Failure process and event types 
77 
Chapter overview 
Chapter 4 shows how to define the risk set and how to set up the data layout for survival 
or event-history data analysis. Survival analysis requires that time to event is defined for 
each individual assigning values to the study start date, the observation end date and the 
censor status variable at the last observation date. Different risk sets definitions exist for 
the analysis of recurrent and multiple events. 
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1. Defining the risk sets for survival (event-history) data 
The risk sets for survival analysis are defined through different possible organizations of 
event-history data in the data layout. This task is accomplished by specifying the 3 
components of the response variable (time start, time stop and censor status), and 
possible different basal risk categories by event number I type (in addition to some 
covariate if necessary) using stratification. Valid risk estimation depends on the extent to 
which data layout organization reflects the nature of the underlying failure process. To 
achieve this goal the following aspects need to be considered: a) classification of the type 
and order of the failure events: whether the events are of different (e.g. dialysis start or 
cardiovascular event) or the same type (e.g., repeated catheter infections), and whether 
they occur with (e.g., repeated infection or rejection episodes) or without natural order 
(e.g., cardiovascular events and infections in the same individual); b) definition of the 
time at risk: when the risk starts and ends; c) consideration of the mechanisms through 
which the predictor is involved in the process: whether I how the same predictor affects 
different outcomes; and d) definition of what is being modelled: the time to each event, 
the total course of a recurrent process or the time segments to each recurring event. 
Different risk sets have been formulated in the past to address different questions while 
fitting recurrent or multiple failure time data (Table 15 and Table 16). 
2. Recurrent failure events of the same type 
Events of the same type may or may not follow a natural order. Catheter infections or 
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Table 15: Risk sets for survival analysis: structure and implications 
Risk set Order I type Example Strata Time zero Modelling Assumptions 
Counting process Ordered I Catheter infections or No Each observation time is Total time course Order not important; 
Same dysfunction episodes; fistula event defined of the recurrent no tied times; same 
thrombosis; repeated process baseline hazard 
peritonitis or transplant 
Stratified Marginal Ordered I rejection recurrences: they Yes Time measured from Total time course Events as independent 
risk sets Same are ordered events in that subject emolment of the recurrent processes; order 
they may be seen in a study process ignored 
that records the time to first, 
Conditional risk Ordered I second, third event, and so Yes Emolment (time Total time course No risk for further 
sets from entry Same on, and the subject is not at measured continuously of the recurrent event until a prior has 
(elapsed time) risk for further events until a from entry) event process occurred 
Conditional risk Ordered I 
prior one has occurred. Four 
Yes Clock set to zero after Time segments layout options are available No risk for further 
sets from event Same for ordered recurrences each event between events event until a prior has 
(gap time) occurred 
Un-stratified Unordered I The same lesion in paired No Time measured from Total time to each The same process for 
Marginal risk sets Same organs such as the eye subject emolment event all events 
Competing risk Unordered I Uraemia and mortality in Yes Time measured from Total time to each Predictor involved in 
sets5 Different Chronic Kidney Disease subject emolment event competing processes 
5 In the absence of correlation and dependent censoring each observation continues until the first event that occurs giving the same results as the 
time to combined event analysis (competing risk model of Lunn-McNeil). In the presence of correlation the observations continue beyond the 
first event that occurs (marginal model ofWei-Lin-Weissfeld), each event can occur only once per subject, ad all subjects are at risk for all 
events. 
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Table 16: Risk sets for survival analysis: example of repeated events in 2 subjects (3 
observed in subject 1 and 1 in subject 2 - models 1 to 6 for event of the same type); and 
triple failure times in other 2 subjects (model 7 and 8 for event of different type). 
ld = 1 ld = 2 Notes 
Model Time Event Str atum Time Event Stratum 
I) Counting processes (O,IOJ I (0,20J I # id records id = # event + I ; order 
(VC) (10, 15] I (20,25] 0 not important; no tied times; same 
( 15,20J I baseline hazard; t experience 
(20,30J 0 broken in event defined egments 
2) Marginal risk sets (0, I 0] I (0,20] I I Strata present but order not 
(VC) (0, 15] 2 (0,25] 0 2 important; start and stop times are 
(0,20] I 3 (0,25] 0 3 the margins of the follow-up 
(0,30] 0 4 (0,25J 0 4 
3) Conditional risk (0, I 0] I (0,20J I I Total time measured continuou ly 
sets from entry - (10,15J l 2 (20,25] 0 2 from entry; stratification keeps 
elapsed time (VC) (15,20J I 3 track of the event# (sequential 
(20,30J 0 4 assumption) 
4) Conditional risk (0, lOJ l l (0,20) l I Clock set to zero after each failure 
sets from event - gap (0,5J 2 (0,5J 0 2 event; stratification keeps track of 
time (VC) (0,5J I 3 the event# (sequential assumption) 
(0, 10] 0 4 
5) Unconditional (0,10] (0,20J l No stratification; same risk set as 
Frailty - elap ed time (I 0, 15] (20,25] 0 the counting process (elap ed time); 
(RE) (15,20] l heterogeneity controlled through 
(20,25J 0 modelling random effects 
6) Conditional Frailty (0, l 0] l (0,20J l l Dependencies controlled through 
- gap time (RE) {0,5J 2 (0, 5] 0 2 stratification; same risk set as the 
(0,5J l 3 conditional from event (gap time) 
{0, I OJ 0 4 
7) Independent (O,IOJ I I (0, 12] 0 I Marginal risk set stratified by event 
Competing risk sets (0, IOJ 0 2 (0, 12] l 2 type; censoring at the t of the first 
(standard) {0, l OJ 0 3 (0, 12J 0 3 event (combined end-point) 
8) Correlated (O,IOJ l l {0,25J l Marginal risk set stratified by event 
Competing risk sets (0,30J 0 2 (0, 12J 2 type; follow-up continues beyond 
(VCI RE) {0,20J 3 (0,20J 3 the fir t event 
Legend: VC = variance corrected method; RE = random effects; unordered events of the 
same type (such as the same eye lesions in either or both eyes where the order does not 
matter) are modelled using a marginal risk sets such as # 8 but without stratification. 
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catheter dysfunction episodes, acute transplant rejection or peritonitis recurrences, A V 
fistula and graft failures are ordered events. In these cases, the underlying failure process 
can be captured in a longitudinal study that records the time to the first, second, third 
event, and so on. A common assumption is that the subject is not at risk for further 
events until a prior one has occurred. Several analytical options are available for this 
type of repeated events within the family of the variance corrected methods and frailty 
models (Table 15 and Table 16): the counting process (26), marginal risk sets (27, 28), 
and the conditional risk sets (29) were originally formulated to address correlated events 
using robust variance methods, but similar risk sets have been proposed using random 
effects modelling (23 - 25). 
As it can be seen from Table 15 and 16, in the counting process model each subject 
becomes a "multi-event counting process" since the total follow-up time of the subject is 
broken into event defined segments, starting from entry into the study with as many 
records per individual as there are events plus one (26). Consequently, the subject returns 
"at risk" once an event has occurred unti l the study ends or observation becomes 
impossible. The ordering is taken into account to some extent by the sequentiality of the 
time pieces. However, the counting process is not stratified thus reflecting the 
assumption of similar basal risk for all events. Averaging potentially different baseline 
risks as events recur may induce bias. This constant basal risk assumption and the 
requirement for lack of tied times are often untenable. Despite these limitations, the 
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theory underlying the counting process and the way the risk sets are organized, make this 
approach appealing for a general approach to recurrent processes. 
In the marginal risk sets model the risk set up is stratified by event number and thus treats 
each failure occurrence as a separate process. This accounts for varying basal risks as 
events recur. However, the marginal risk set actually ignores the event ordering as the 
time at risk begins at the initial observation time for all records - e.g., the possibility that 
a person is at risk for the fourth access failure before the first access has even failed is not 
excluded (27). This model may be useful to model the total time to each of the possible 
recurrent events, allowing basal risks to differ but with no strict order assumption. Such 
a model may be useful to model repeated hospitalizations from different causes, where 
the orderable event of the same time is represented by the hospital admission and the 
possible basal risk change after each episode is accounted for by stratification. 
The assumption of the conditional risk sets model is that each patient is not at risk for a 
further event until a prior has occurred (29). Two variations with different time scales 
and risk sets have been implemented and both stratify the data by event number so that 
the baseline hazard is allowed to vary with each event. In the conditional risk sets model 
from entry (elapsed time) the data is set up as for the counting process (t measured from 
entry). This latter variation is useful when modelling the full time course of the recurrent 
event process. In the conditional risk sets model from previous event (gap time) the 
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clock is reset at each event (t from previous event with zero time at the beginning of each 
follow-up segment). This variation is useful to model the gap time between events. Both 
models are stratified by failure order to track the event number. The structure of the data 
set up reflects this sequence or ordering assumption (conditional risk). However, elapsed 
time estimation produces the hazard of an event since the study began, while the gap time 
fonnulation gives the hazard since the previous event. The choice of gap versus elapsed 
time approach depends on the research question at hand. Using gap time presumes there 
are substantive reasons to believe that the 'clock should restart' after each event in order 
to determine the effect of the covariates on subsequent events (e.g., when a previous 
infection has been cleared prior to the next catheter placement). In this case estimated 
effects mirror how the co variates affect the risk of failure for each access. In contrast, 
elapsed time models assess the effect of the covariates on the risk offailure from the start 
of the study through to the end (e.g., when there is no reason to reset the risk clock 
because the risk accumulates since entry). In such a case the estimated effects reflect 
how the co variates affect the risk of failure over the entire course of the recurrent event 
process. 
Data set up for frailty models are the same as those of the conditional risk sets from entry 
(traditional un-stratified frailty) and previous event (stratified or conditional frailty). The 
heterogeneity between individuals I clusters is taken into account through modelling 
random effects. Stratification is an additional tool to control for the dependencies among 
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the failure times. 
Examples of modelling ordered events of the same type using the AV access data will be 
discussed in chapter 5 and 6. 
3. Unordered failure events 
For unordered events of the same type (such as the same retinal lesions of either eye) the 
un-stratified marginal risk sets has been used (23). However, this recurrent failure 
process is not so common. For unordered events of different type, such as infections, 
rejection episodes and death in a follow-up study of transplant patients, the suggested risk 
set is the marginal risk sets. This risk set is stratified by event type to allow basal risks to 
vary (Table 15 and 16). Instead, the coefficients are restricted to be the same across 
strata, although stratum specific effects can be incorporated into the model. Other 
nephrology examples of failures of different types include diverse adverse reactions to 
therapy in an intervention trial, or uraemia and mortality in a follow-up study of chronic 
kidney disease patients (5 - 8). These events are unordered because they occur in 
random sequence. Depending on whether events are correlated or not, two different 
approaches are available. 
In the absence of correlation and dependent censoring the competing risk model has been 
suggested for analysis (28). In this case the likelihood of being censored at timet does 
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not depend on the reason for censoring including failure from a competing risk. The 
competing risk model is stratified by event type (basal risk allowed to differ) and gives 
the same results as the combined end point analysis (time to the first event that occurs) 
with the data layout containing only one record per subject. In the competing risk set the 
number of observations per subject is a multiple of the number of considered events (if 
there are k possible events, each subject will appear k times in the data layout, once for 
each possible failure). All failure times within the same subject begin at the same 
observation start date and continue until the follow-up end date in the absence of any 
event. If one or more event occurred the first event date is the termination time for the 
corresponding event type record and the censoring date in the remaining records from the 
same individual. Further events after the first are consequently ignored as in the 
combined end-point with one record per subject approach. The advantage of the larger 
data set is that it allows for easy estimation of within-event-type coefficients (stratum 
specific effects). The variance correction is not necessary in this independent competing 
risks model as each subject may have at most one event (23). 
When there are reasons to believe that the data are correlated, it is possible to analyse 
multiple events per subject using the marginal model ofWei-Lin-Weissfeld (27). As in 
the previous model all times are measured from the date of patients' enrolment (time 
zero) but each observation continues in each stratum beyond the first event that occurred. 
An important characteristic of these failure events is that each can occur only once per 
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subject and that all subjects are at risk for all events as in the un-correlated competing 
risk sets model. This model is appropriate when the predictors under investigation are 
plausibly involved in the pathways leading to more than one event type and, therefore, 
the censoring mechanism for one event may be informative for the other. For example, 
plasma levels of asymmetrical di-methyl-arginine (ADMA) have been shown to predict 
both progression of chronic nephropathies and death in patients with chronic kidney 
disease (5). In these situations, the terminating time for observing one event could be 
correlated with the other and, as a result, the assumption of independent censoring may 
be violated. In addition, considering only time to the first event that occurs reduces the 
study power. The variance corrected and frailty approaches (with stratification by event 
type) make better use of the information in the data and the analyses are thus more 
powerful. 
Examples of modelling unordered events of the different type using the chronic kidney 
disease data will be discussed in chapter 5. 
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5) Chapter 5: Semi-parametric Cox's model 
88 
Chapter overview 
Chapter 5 introduces extensions of the Cox's model for correlated events of the same type 
(recurrent events) or different type (multiple events). Both pragmatic (variance 
corrected) and random effects (frailty) method are available for Cox's regression. The 
dialysis access data are used as example of recurrent event analysis. The Vitamin D data 
are used as example of multiple event (competing risks) analysis. 
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1. Variance corrected and frailty models for recurrent events of the same type: 
the A V access data revisited 
Repeated failure time models can be fitted using the Italian A V access study data. Table 
17 reports the estimates of the effect of the interaction between heart failure and late 
referral on the risk of A V access failure from models of time to the first event ( 1 record 
per subject, N = 535), and time to multiple events per subjects for ordered events of the 
same type (variance corrected and frailty models). 
From the table it can be seen that the confidence intervals for the estimated effect of the 
interaction are wider (greater P value) in standard survival analysis than those from 
models for repeated events. This is a consequence of the smaller sample size (smaller 
event number). However, the coefficient estimates are close, indicating that such effect 
may be the same for any A V access created in the same patient. The stratum by covariate 
interaction is a formal way to test such hypothesis (not supported by these data). 
The counting process fonnulation provides a slightly higher effect estimate as compared 
to the time to first event analysis. However, such estimate may be biased since the 
absence of stratification may fail to control for potentially different baseline risks as 
events recur and these "baseline" risks are averaged (23). 
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Table 17: Multiple primary failure time models for ordered events of the same type 
(access failure): fits of the effect of the interaction between heart failure and late referral 
on the risk of arterio-venous (A V) access failure. Models include the main effects (heart 
failure and late referral) and are controlled for history of vascular diseases (cerebral, 
peripheral and coronary artery diseases), and A V graft vs. fistula. All models are 
independent of gender, BMI, proximal vs. distal location, centre effect, diabetes, 
hypertension, chronic lung and systemic diseases. 
Model N F Beta NSE RSE P (P=O) HR Cl9s for Theta p (0=0) 
HR 
First event 535 222 0.671 0.363 0.377 0.075 1.96 0.934, 4.1 NA NA 
C Process 700 310 0.793 0.298 0.329 0.016 2.21 1.16,4.21 NA NA 
Marginal 2140 310 0.946 0.298 0.404 0.019 2.58 1.16, 5.68 NA NA 
Elapsed T 700 310 0.734 0.307 0.308 0.017 2.08 1.14,3.81 NA NA 
Gap time 700 310 0.701 0.302 0.303 0.021 2.02 1.11,3.65 NA NA 
U Frailty 700 310 1.180 0.465 NA 0.011 3.25 1.31, 8.09 1.04 <0.01 
C Frailty 700 310 0.701 0.302 NA 0.020 2.02 1.12, 3.64 <0.01 0.670 
Legend: N =number of records,· F =number of failures; Beta (fJ): regression coefficient; 
NSE: nai"ve standard error of beta; RSE: robust standard error (adjusted for clustering 
on patient identity); P (fJ=O): two-tailed significance level for hypothesis testing (using 
RSE of beta) of Beta being = 0; HR and C/95jor HR: hazard ratio and 95% confidence 
intervals for hazard ratio estimate. Theta (8) variance ofthefrailty (gamma 
distribution); P (8=0): two-tailed significance level for hypothesis testing of() being= 0. 
C Process: counting process; Elapsed T: elapsed time (from entry); VIC: unconditional 
and conditional frailty models. 
91 
Table 18: Multiple secondary (assisted) failure time models for ordered events of the 
same type (access failure) : fits of the effect of heart failure on the risk of arterio-venous 
(A V) access failure. Models are controlled for late referral, history of vascular diseases 
(cerebral, peripheral and coronary artery diseases), and A V graft vs. fistula. A II models 
are independent of gender, BMJ, proximal vs. distal location, centre effect, diabetes, 
hypertension, chronic lung and systemic diseases. 
Model N F Beta NSE RSE P (Jl=O) HR Cl9s for Theta p (0=0) 
HR 
First event 535 176 0.429 0.192 0.198 0.030 1.53 1.04, 2.27 NA NA 
C Process 700 245 0.451 0.161 0.186 0.016 1.57 1.08, 2.26 NA NA 
Marginal 2140 245 0.506 0.163 0.223 0.023 1.65 1.07, 2.57 NA NA 
Elapsed T 700 245 0.389 0.164 0.162 0.016 1.48 1.07, 2.03 NA NA 
Gap time 700 245 0.389 0.162 0.160 0.015 1.47 1.07, 2.02 NA NA 
U Frailty 700 245 0.507 0.208 NA 0.015 1.66 1.10,2.50 0.89 <0.01 
C Frailty 700 245 0.389 0.162 NA 0.017 1.47 1.07, 2.03 <0.01 0.900 
Legend: N = number of records; F = number of failures; Beta (fJ): regression coefficient; 
NSE: nai"ve standard error of beta; RSE: robust standard error (adjusted for clustering 
on patient identity); P (fJ=O) : two-tailed significance level for hypothesis testing (using 
RSE of beta) of Beta being = 0; HR and Cl9sfor HR: hazard ratio and 95% confidence 
intervals for hazard ratio estimate. Theta (B) variance of the frailty (gamma 
distribution); P (8=0) : two-tailed significance level for hypothesis testing ofB being = 0. 
C Process: counting process; Elapsed T: elapsed time (from entry); UIC: unconditional 
and conditional frailty models. 
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In agreement with simulation studies, the marginal formulation provides an even larger 
estimated effect probably due to the lack of any order implication of the risk set 
organization (23). 
Point effect estimates from conditional models (both variance corrected and stratified 
frailty models) are closer to those of time to first event (standard) analysis than all other 
models. In addition, the underlying assumptions of these risk sets is consistent with the 
biological and clinical understanding of some recurrent event processes such as A V 
access failure. Conditional models assume event time sequentiality (ordering) and 
varying basal risks, achieved through event stratification and specific risk times definition 
(i.e., elapsed times from entry, or gap times from previous events). Most importantly, 
this may impact on the dependencies among the failure times. This problem can be 
studied looking at the model standard errors. 
Considering the variance corrected methods, it can be seen from Table 17 that the robust 
standard errors of the estimators are higher in all non-conditional models. The counting 
process and the marginal model do not address the sequential nature of the event order 
and assume independence in their structure (the former is not stratified and the second 
has a marginal time structure, i.e. the time at risk starts at the initial follow-up date for all 
records). This fact induces higher errors. As mentioned, correction for robustness is 
based on these errors. Since in the conditional models the sequential nature of the order 
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of events mostly accounts for the lack of independence, the variance correction in the 
calculation of the robust standard errors has very little effect (little difference between the 
nai"ve standard errors and the corresponding robust standard errors of the estimated 
coefficients). This feature of conditional models makes them especially attractive for 
multiple access failure because they account for both potentially different baseline 
hazards and event order. 
Random effects modelling offers further insight about the sources of correlation in the 
data. Frailty models indicate that the true data generating process is characterized by 
significant individual (cluster) heterogeneity. In fact the variance of the random effects 
(theta) is significantly different from zero according to the standard unconditional (un-
stratified) frailty model. However, this heterogeneity disappears when the model is 
stratified. This suggests that the heterogeneity is induced by event dependence as the 
main source of correlation in the data. In other words, it may not be simply that some 
individuals are predisposed to access failure in general because of continuing factors such 
as tendency to thrombosis. It seems rather that once a failure has occurred in susceptible 
(frail) individuals, consequences such as having to use sub-optimal vessels increase the 
risk of subsequent failure events. 
The same results are obtained analysing the effect of heart failure on the risk of 
secondary (final or assisted) AV access thrombosis (Table 18). Point estimates from 
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conditional models are the closest to those from the standard time to first event model, 
and little residual dependencies are addressed by robust errors. In addition, conditional 
solutions to both primary and secondary survival modelling offered better fits (standard 
model diagnostics and assumption verification analysis not shown). 
2. Variance and frailty models for multiple failure events of different type: the 
vitamin D data revisited 
Unordered events of different type such as chronic dialysis initiation and death in chronic 
kidney disease patients can be studied as a function of some exposure of interest using 
marginal models (5 - 8). If the exposure is supposed to be associated with an event only 
multiple failure time analysis is not necessary. In such a case, the association of the 
predictor with either event may be tested using standard time to single event analyses 
first. For example, if the predictor is associated with death only, such as Urotensin 11 in 
chronic kidney disease (7), the other event (dialysis status) may be treated as a time 
varying covariate (absent versus present) if it is supposed to change the risk for the final 
event (death). In other cases the exposure under study is thought to be associated with 
multiple events (such as ADMA and the risk of both requiring dialysis and death). When 
failure times are correlated the marginal risk sets model offers interesting analytical 
solutions (5, 6). Both time varying covariate and event specific effects can be 
incorporated into these models (8). 
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In a recent study Vitamin 0 deficiency predicted greater risk for dialysis and death 
among Vitamin 0 nai've chronic kidney disease patients (8). Vitamin D deficiency is 
defined as levels of 25-hydroxy-vitamin 0 below 15 ng/ml (i.e., inadequate levels of the 
nutritional or storage form of Vitamin 0). Although Vitamin D is mainly seen as a 
compound pivotal for bone physiology it is also central to optimal functioning of other 
organ systems including the cardiovascular, endocrine and immune systems. The study 
hypothesis was that Vitamin 0 deficiency may be a condition associated with (a marker 
of) both progression to dialysis and death. 
Table 19 reports the estimates ofthe effect of Vitamin 0 deficiency on the risk for 
dialysis or death in 168 patients with chronic kidney disease (8). The record number is 
greater than the number of subjects even in time to single event models because some 
covariates were allowed to vary over follow-up (time dependent models). However, the 
constant proportionality assumption held for all such models (as well as for multiple 
failure times models) particularly once updated covariate values were modelled (9 - 13). 
From Table 19 it can be seen that the effect of Vitamin 0 may differ by event type, being 
greater on the risk for dialysis than the risk for death. The observational nature of the 
study does not allow causal inferences regarding either of such effects, provided that they 
exist. In other words, causal effects are possible, but it is just as possible that Vitamin D 
levels decline as people near dialysis or death. This is true also for multiple failure times 
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Table 19: Multiple failure time models for unordered events of different type (dialysis 
and death): fits of the effect of Vitamin D deficiency (initial follow-up levels < 15 ng/ml) 
on the risk of dialysis (standard model), death (standard model), dialysis or death 
(independent competing risks - combined end-point) and dialysis and death (correlated 
competing risks - double end-point). 
Model N F Beta NSE RSE p (J3=0) HR Cl9s for T heta p (9=0) 
HR 
Dialysis 406 48 0.969 0.370 0.295 0.001 2.63 1.48, 4.70 NA NA 
Death 406 78 0.731 0.297 0.267 0.006 2.08 1.23, 3.51 NA NA 
LMN 812 105 0.889 0.256 0.203 <.001 2.43 1.63, 3.63 NA NA 
WLW 812 126 0.825 0.230 0.198 <.001 2.28 1.55, 3.37 NA NA 
Frailty 812 126 0.825 0.231 NA <.001 2.28 1.45, 3.59 <0.01 0.92 
Legend: Cox's models controlled for time-varying levels of kidney function, phosphate 
and use of angiotensin antagonists (both events); proteinuria (dialysis); and heart 
failure, age, smoking habit, C-reactive protein, serum albumin (death) . All models are 
independent of gender, BMJ, season, other co morbidities or therapies (including 1,25 VD 
supplements), and labs (including 1,25 VD). N: record#; F: event #; Beta (/3): effect of 
25 VD deficiency; NSE: naive standard error of beta; RSE: robust SE (adjusted for 
clustering on patient identity); P (/3=0): two-tailed significance /eve/for hypothesis 
testing (RSE of/3) of/3 = 0; HR and C/95 jor HR: hazard ratio and 95% confidence 
intervals for HR estimate. Theta (B) : variance of the frailty (gamma distribution); P 
(8=0): two-tailed significance /eve/for hypothesis testing of() being = 0. LMN: 
independent competing risk sets (Lunn-McNeil); WLW: correlated competing risk sets 
(Wei-Lin- Weissfeld). 
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Table 20: Multiple failure time models for unordered events of different type (dialysis 
and death): stratum specific effects of Vitamin D levels at the date of nephrology referral 
on the risk of dialysis or death (independent competing risks - combined end-point) and 
dialysis and death (correlated competing risks - double end-point). 
Model N F Beta NSE RSE p (Jl=O) HR Cl9s for HR 
I =dialysis 406 48 0.968 0.370 0.295 0.001 2.63 1.47, 4.70 
LMN 
2 = death 406 57 0.814 0.356 0.308 0.008 2.26 1.23, 4.14 
WL W 1 = dialysis 406 48 0.968 0.370 0.295 0.001 2.63 1.47, 4.70 
2 =death 406 78 0.731 0.297 0.267 0.006 2.08 1.23, 3.51 
Legend: Cox's models specification as described in Table 19legend. The exposure is 
Vitamin D (2 5 VD) deficiency (levels < 15 v > = 15 ng/ml) at the date of nephrology 
referral. Nand F: stratum size and event#; Beta (p): effect of25VD deficiency; NSE: 
nai've standard error of beta; RSE: robust SE (adjusted for clustering on patient identity); 
P (P=O): two-tailed significance level for hypothesis testing (RSE ofPJ ofP = 0; HR and 
CJ95 for HR: hazard ratio and 95% confidence intervals for HR estimate. LMN1/LMN2: 
stratum specific estimates from the LMN (Lunn-McNeil) independent competing risk sets 
model; WLW1/ WLW2: stratum specific estimates from the WLW (Wei-Lin-Weissfeld) 
correlated competing risk sets model. 
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analyses. 
Considering the first event (independent competing risks), 48 patients required dialysis 
and 57 deaths occurred in 168 subjects over follow-up (105 combined end-points). 
However, 21 subjects died subsequent to starting dialysis and if it is believed that dialysis 
and death are not independent (i.e., those experiencing greater risk for dialysis may also 
be at higher risk for death), 126 total events could be modelled using a variance con·ected 
or frailty approach. In the presence of data correlation the reasons for censoring due to a 
competing risk may violate the non-informative censoring assumption. 
Assuming the effect of Vitamin D on dialysis and death to be the same, the independent 
competing risks approach estimate is less precise, possibly because of power loss. In 
addition, the point estimate is greater than the correlated event model. Checking the 
results from single event models, and stratum specific effects (Table 20 - see below) it 
may well be that the composite event approach is inaccurate. Of note, the difference 
between naive and robust standard errors is not as evident as it was in marginal models 
for ordered events shown in the previous chapter. This may be due to the fact that the 
risk sets include updated covariate values (defined as sequential elapsed times) and the 
measurement of only two possible events per subject. Finally, the frailty model shows 
that the evidence in support of heterogeneity is very weak if the model is stratified by 
event type (as recommended for competing risks studies). 
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The estimates in Table 20 are from models including stratum specific effects, the effect 
of Vitamin Don dialysis and death under the independent competing risks asswnption 
and effect of Vitamin Don dialysis and death under the correlated competing risks 
assumption. The results of these models differ not only in terms of point estimates but 
also in terms of precision. However, the difference in precision may be simply the result 
of different model power, again being greater for the correlated competing risk model. 
Importantly, the point estimates from this last model only are practically the same as 
those from standard time to each event models. Thus, if it is believed that Vitamin D 
deficiency is associated with both outcomes (and thus there are reasons to believe that the 
independent censoring assumption is violated), the correlated competing risks solution 
may be a better choice. 
What are the advantages of using a single model for two possibly correlated outcomes as 
opposed to two separate models for each if under the same specification they offer the 
same estimates? First, there is a clear power advantage. If the two single event models 
have some covariates in common (as was the case for phosphate), or stratifying variables 
(as was the case for levels of kidney function and use of converting enzyme I angiotensin 
receptor blockade), a greater nwnber of additional predictors (following the rule often -
one parameter estimate every ten events) can be included into the model, and more 
freedom is left for testing interactions and potential confounders. Of note, for the 
100 
purpose of comparability, the single event models, the independent multiple event model 
and the correlated event model were all specified in the same way (in terms of stratum 
specific and common effects and stratification). Results would differ if adju tment was 
made by including the covariate in the model instead of using stratification (8). Second, 
if a decision ha to be made as to whether to believe or not in a similar effect on both 
outcomes based on the data, the correlated event model with stratum specific effects 
offers the advantage of double estimation, and even statistical testing of such possible 
effect difference. 
The power implications of including additional events after the first can be assessed 
comparing the standard errors of the combined end-point model and the correlated 
(variance corrected) event model (e.g. , Table 19). Prior to conducting any analysis the 
expected information gain was 20% (1 26/ 105). However, the variance change was 
slightly greater at 23.8% (ratio of the nai"ve variances). Thus, it is expected that each 
repeated event is worth at least as much as but probably even more than a new first event. 
This happened to be the case in this example. In fact, the expected na"ive standard error 
(NSE) of the coefficient associated with Vitamin D deficiency in the multiple event 
model (event number 126) was close to (but slightly greater than) the estimated value 
from the model, and greater than the robust standard error (RSE). This expected NSE 
equals the observed NSE of the combined end-point model times the square root of the 
proportion of independent events: 0.256 * .../(105/126) = 0.233 (vs. the estimated values of 
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0.230 for the NSE and 0.198 for the RSE. Thus, the corresponding expected event 
number was (0.256*~105) I 0.198 to the power of2, i.e. 175.5. This resulted in a realized 
information gain of (175 .5 - 1 05)/(126- l 05) = 3.35. In other words, each further 
multiple event was worth about three times of a new first event (event number gain = 69). 
Time independent models (i.e., models without time varying covariates) fitted to the 
same study data (8) resulted in similar infonnation gain (ratios greater than one). Similar 
findings were obtained in different studies (23). These information analyses from 
observational data are important as they can be used to plan an event driven clinical trials 
whereby study size and duration are a function of the event number. For example, 
randomized clinical trials of an intervention impacting more than just one outcome can be 
planned to record multiple events in the same subjects. This is important because 
extending follow-up of fewer subjects can often be Jess costly than shorter follow-up of 
larger samples, and similarly efficient, provided that the information gain deriving from 
additional events in the same subjects is reasonable, the likelihood of experiencing 
further events is high, or the number of possible additional events is high. When there 
are reasons to believe that the intervention under study may affect a multiple failure 
events process, prior information data from observational studies may be used to estimate 
the infonnation gain deriving from such multiple failure times measurements. 
One obvious question at this point is whether different outcomes could be weighted 
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according to severity. For example, investigators planning a trial of Vitamin D 
supplement in chronic kidney disease may believe that patient death is twice as 
momentous as renal death, but still be willing to use both outcomes to compare 
intervention and control groups. This can be easily accomplished by giving each 
observation in the death stratum a weight of 2 and reassessing the information gain 
resulting from the use of further events in the same subjects. 
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6) Chapter 6: Parametric analysis of correlated recunent events: the access data 
revisited 
104 
Chapter overview 
Chapter 6 introduces fully parametric approaches to correlated recurrent events. Dialysis 
access data are used as example for either event count modelling or repeated failure time 
regressiOn. 
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1. Models for event counts 
The A V access study was planned to collect event history (survival) information on the 
first and further A V accesses created in an incident cohort of hemodialysis patients 
during a 6 year follow-up. These survival data can be aggregated by combination of the 
level of relevant covariates, leading to grouping of exposure times and sum of failure 
events (counts). Such data aggregation resulted in 78 records for primary failure count 
analysis and 80 records for secondary failure count analysis from the AV access study. 
Alternatively A V access level information can be used for count models assuming that 
the underlying failure process follows a Poisson distribution. 
Table 21 and Table 22 report the effect of the interaction between late referral and heart 
failure on the risk of primary and secondary failure of any A V access created in the 
patients during follow-up. There were no stratum specific effects of any of the covariates 
in the models. All models are controlled for the effects of the main terms (late referral 
and heart failure), vascular disease, access type (prosthetic graft versus native fistula) and 
time bands (0-3, 3-6, >6 months). This last adjustment was necessary to reasonably meet 
the constant baseline incidence rate assumption implied by the adopted model. 
Models of aggregated data 
For each failure type (primary and secondary failure) five models are presented in Table 
21: the first is the standard Poisson model; the second is its robust variance version; the 
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Table 21: Models for count data: aggregated data set 
Models p SE Exp(p) Cl9s of Exp(p) P (P=O) Extra parameters 
Poisson (1) 0.704 0.298 2.02 1.12, 3.62 0.018 
Poisson (2) 0.679 0.326 1.97 1.04, 3.74 0.037 
RSE Poisson (1) 0.704 0.236 2.02 1.30, 3.21 0.003 
RSE Poisson (2) 0.679 0.246 1.97 1.38, 3.20 0.006 
SSE Poisson (1) 0.704 0.375 2.02 0.96, 4.22 0.061 Scale = 1.58 
SSE Poisson (2) 0.679 0.324 1.97 1.04, 3.72 0.036 Scale = 0.98 
BS Poisson (1) 0.704 0.294 2.02 1.13, 3.60 0.017 
BS Poisson (2) 0.679 0.288 1.97 1.12, 3.47 0.019 
NBR (robust) (1) 0.704 0.236 2.02 1.30, 3.21 0.003 8 = 0 
NBR (robust) (2) 0.679 0.246 1.97 1.38, 3.20 0.006 8 = 0 
Legend: Estimated effects of the interaction between late referral and heart failure from 
models of primary (1) and secondary (2) AV access failure. All models are controlled for 
the main terms (late referral and heart failure), access type (graft versus fistula), 
vascular disease and time band effects (0-3, 3-6, >6). N of records are 78 (1) and 80 (2) . 
{J: beta coefficient (log-rate d!fference); SE: standard error of{J; Exp({J): Incidence Rate 
Ratio; C195: 95% Confidence Intervals of Exp({J); P value of the null hypothesis ({J=O); 8: 
variance of the random effect (gamma distribution); RSE: robust SE; SSE: SE scaled 
using the square root of Pearson X2-based dispersion; BS: bootstrapping; NBR: negative 
binomial regression. 
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Table 22: Models for count data: A V access level data 
Models p SE Exp(Jl) CI95 of Exp(Jl) P (Jl=O) Extra parameters 
VC Count Models 
RSE Poisson (1) 0.704 0.314 2.02 1.09, 3.74 0.025 
RSE Poisson (2) 0.679 0.335 1.97 1.02, 3.89 0.043 
GEE (robust) (1) 0.689 0.317 1.99 1.06, 3.71 0.030 18 p parameters 
GEE (robust) (2) 0.841 0.376 2.31 1.1 0, 4.84 0.025 18 p parameters 
RE Count Models 
Rl Poisson (1) 1.675 0.598 5.34 1.65, 17.2 0.005 e = 2.7 (1.6, 3.8) 
Rl Poisson (2) 1.060 0.504 2.88 1.07, 7.75 0.035 e = 1.1 (0.0, 2.2) 
RC Poisson (I) 1.665 0.597 5.28 1.63, 17.0 0.005 e11 = 2.8 (I .4, 4.2) 
e12 = -0.1 (-.3, .15) 
en = 0.1 (0.0, 0.2) 
RC Poisson (2) 1.054 0.506 2.87 1.06, 7.75 0.037 e11 = 1.1 co.o, 2.3) 
e12 = 0.0 (0.0, 0.0) 
e22 = 0.0 (0.0, 0.0) 
Legend: Estimated effects of the interaction between late referral and heart failure from 
models of primary (1) and secondary (2) A V access failure, controlling for the main 
terms (late referral and heart failure), access type (graft versus fistula), vascular disease 
and time band effects (0-3, 3-6, >6). N of records: 700; number of clusters (subjects) : 
535. /]:beta coefficient (log-rate difference); SE: standard error of/]; Exp(/3): Incidence 
Rate Ratio; CI95.' 95% Confidence Intervals of Exp(fJ); P value of the null hypothesis 
({3=0); (}:variance of the random effect (normal distribution); RSE: robust SE; GEE: 
generalized estimating equations; RE: random effects; Rl: random intercept only; RC: 
random coefficients (intercept and slope, and their covariance). Variance subscripts for 
the random effects (95% CI): (}11 = Rl (extra-variation due to subjects), B22 = RC (extra-
variation due to varying response to time bands), B12 =covariance of R1 and RC. For 
both (1) and (2) the variance of the RC ((}22) was not significantly different from zero (NS 
likelihood ratio test of the RC and nested Rl model). 
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third is its "Pearson chi square" scaled residual version; the fourth is its bootstrapping 
residual version; and the last is the negative binomial model with robust standard errors6. 
Results from all models indicate that the risk of both primary and secondary failure is 
twice as high in the presence of both late referral and heart failure (whereas each factor 
alone does not alter the incidence rate significantly - not reported but consistently found 
in all interaction models). Point estimates from robust, scaled and bootstrapping Poisson 
regression models are the same as those from the standard version of the model (as they 
must be) because these models correct the coefficient "variance" for the dependencies in 
the data. Of note, robust methods generate smaller standard errors in this example (with 
narrower confidence intervals) than standard Poisson regression (usually the opposite 
happens) and the residual scaling approach. Scaled variance models show that if a 
variance inflation exists, such inflation affects only primary failure data (scale > 1). 
6 Unlike the normal distribution the Poisson distribution has no separate parameter for the variance but 
this is equal to the mean. More precisely, the variance is a function of the mean with dispersion 
parameter q> = I (whereas the variance of the nonnal distribution is an identity function of the dispersion 
parameter q> = a 2) . Different approaches exist to account for the extra-variability in the parameter J.1 of 
the Poisson distribution (i .e., if the variance is greater than the mean) due to omitted covariates or 
correlation in the data. One way is to allow 1.1 to vary randomly to some extent (i.e ., the variability 
unexplained by fixed effects) according to some (prior) distribution and assume that conditional on that 
random variation the response variable follows the Poisson distribution (random effects models). There 
are also pragmatic ways to address the problem of over-dispersion. One way is to assume that the 
variance is proportional to the variance function but estimating a dispersion or scale parameter q> rather 
than assuming the value of I appropriate for the distribution. This scale parameter can be estimated 
from the deviance or Pearson chi square I:(y - 1.1i I V~, where V ~ reduces to J.1 under the Poisson model. 
This scale parameter is then used to estimate the standard errors of the regression coefficients (quasi-
likelihood estimation). Robust methods offer empirical estimates of the standard errors by removing 
the observations one at a time in the process of computation (one cluster at a time when clustering 
information is available - chapter 3). Finally in bootstrapping the sample is resampled with 
replacement to approximate what would happen if the whole population were sampled, and estimate the 
coefficients and their variance. 
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Negative binomial models incorporate also a random effect term in the equation, which 
may generate point estimates different form those of the standard Poisson model. This 
random effect is "record specific" or, more properly "combination specific" since data 
are aggregated (as opposed to "cluster specific"), and its variance is estimated from a 
theoretical distribution. There is no evidence from the data of this example that the 
variance of such random factor (if it exists) is different from zero. This indicates that the 
aggregated data do not show important heterogeneity. Results of the negative binomial 
regression were the same using standard rather than robust variance estimation (not 
shown). This means that once available information has been accounted for (including 
interaction terms between time bands and access number in these models) there remains 
little extra-variability in the data (over-dispersion)7. 
Count model of A V access level data 
Count data can be analysed using the A V access information. One way is to treat the 
correlation among A V accesses from the same subjects using variance conection 
(although scaled residuals and bootstrapping are other possible approaches). Variance 
correction in such cases is made considering clusters of observations, i.e. treating 
7 The Poisson distribution assumes that the variance be equal to the mean. This assumption is often 
violated in real life count data which presents variance greater than the mean (over-dispersion). Other 
common complications are zero inflation (excess zeros in the data) or zero truncation by designs (for 
example enrolment of subjects experiencing events only, or exclusion from the analysis of those 
without event). Negative binomial regression is useful to account for extra-variability unexplained by 
the measured covariate. Negative binomial versions for zero-inflated or zero-truncated models exist. 
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observations from different clusters as independent. Both variance corrected models 
replicate the results of aggregated data. In addition to variance correction (cluster robust 
variance), generalized estimating equations incorporate the assumed correlation structure 
of the data in the variance estimation. As opposed to correcting the estimators' variance 
only, this can have an impact on the point estimates. An unstructured working 
correlation matrix has been specified for these data as this is the most flexible - although 
the least parsimonious - approach (Table 14). GEE use the suggested working 
correlation to start the iterative estimation process, and then refine the estimates of the 
correlation matrix values using the observed data. From Table 21 it can be seen that 
results provided by these regression methods are consistent with those from previous 
models. The additional (nuisance) parameters estimated by the GEE are those of the final 
working correlation matrix from which the standard errors of the coefficients are 
estimated (values not shown). 
Table 22 shows that the estimates generated by random effects Poisson models differ 
from those of pragmatic methods, especially for primary failure models (where 
aggregated data analysis showed the existence of some amount of extra-Poisson 
variation). It is possible that splitting some observations into time bands to account for 
the effect of time (to meet the constant incidence rate requirement) may have induced a 
type of over-dispersion that random effects fail to account for, or require extra-work to be 
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managed properll. In fact, estimates were even larger if the chosen distribution for the 
random effects was the gamma distribution, rather than the chosen normal distribution 
(not shown). This limitation should not be seen as a limitation of random effects models 
in general, but rather as a problem related to the data set example chosen for the current 
discussion. The additional parameters estimated by random effects models are the 
variances of the frailties (or random effects). In the first two models only a random 
intercept has been asswned. Additional random effects (random slope in the last two 
models) did not improve significantly the model fit (non significant likelihood ratio test, 
not shown). However, these random coefficients models are reported to show the amount 
of extra-parameter estimation. It is important to notice that for any pair of random effects 
(1 intercept and 1 slope for example, but similarly for two slopes or two intercepts) the 
model estimates 3 parameters: the two variances plus the covariance of the two random 
effects. More generally, the number of estimated parameters in an "n" random effects 
model equals n + n*(n - 1) I 2. For example, if the data contains two levels of clustering 
(e.g., one intercept for centre and one intercept for subject) and two random slopes (e.g., 
individual change in the response due to age and time), then the model will estimate n = 4 
random effects plus 6 covariances (for a total of 10 parameters). An advantage of mixed 
effects modelling is the possibility to specify more than one level of correlation in the 
data and different types and number of random effects (intercepts and slopes). However, 
8 For example, a within group correlation structure may need to be specified often for the computation of 
the residual matrix. This is done when the correlation in the data is not fully accounted for by the 
random effects (i.e. , residual correlation remains after the random effects have been fitted). Some 
packages only are currently capable to run such models (S-Pius, R and SAS). 
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a thorough consideration of the benefits deriving from the inclusion of more than two or 
three random effects should be assessed carefully. In fact software procedures for non-
linear mixed effects models currently run very slowly when estimation of random slope 
variances is required. 
The current A V access data have only two layers of random errors (AV access at the 
lower level and subject at the higher level). Random effects due to subjects are meant to 
adjust for the error dependencies at the lower level. These random effects due to subjects 
were estimated through the random intercept only, though the amount of change in the 
incidence event rates as other covariates change may vary significantly by subjects 
(additional random slopes). There was no centre effect (upper level correlation), 
probably because the three participating centres were characterized by very similar 
policies and patient characteristics (centre random effects estimation would require a 
larger number of centres for reliable estimation). The variance "theta" reported in Table 
22 refers to: 1) the extra-variability in the intercept (baseline incidence rate or incidence 
rate when all the model covariates are set to zero - or to the mean for continuous 
variables) unexplained by the covariate and due to subject characteristics (Rl models); or 
2) both to the intercept and slope or "extra-change" in the incidence as time passes by 
(RC models). This random slope estimates the extra-variability of the effect of time band 
due to different impacts of the effect of time in different subjects. Two additional 
parameters are estimated in RC models: the variance of the random slope and the 
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covariance between random intercept and slope (or correlation, if the covariance is 
divided by the product of the respective standard deviations). The sign and the size of 
this correlation between random effects is important. From this correlation it is possible 
to estimate the size and direction of the extra-variability in the response variable as the 
values of the slope covariate changes (heteroskedasticity). Prediction of the response by 
levels of the fixed effects of interest can be estimated taking into account both the 
residual error (standard errors) and the random variation components (intercept, slope and 
their covariance). The meaning of either one, or several random effects is the same: they 
account for the extra-variability in the data (called frailty for risk data) unexplained by 
the (fixed) covariates. If the mixed model is correctly specified, the estimated fixed 
effects are true (unbiased) conditional on the frailty effects. These effects (parameters) 
are interpretable as individual effects, as opposed to the population average effects 
estimated by marginal (robust) methods described above. 
2. Models for repeated failure times 
Different survival models can be fitted to the A V access data to estimate the effects of the 
interaction between late referral and presence of heart failure. 
Robust methods 
Table 23 shows the results from three robust variance models of primary and secondary 
AV access survival: the semi-parametric Cox's model in its gap time (conditional from 
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Table 23: Robust (cluster) survival models for continuous failure times data 
Models p SE Exp(p) Cl9s of Exp(p) P (p=O) Extra parameters 
GT Cox's (1) 0.752 0.300 2.12 1.17,3.82 0.012 Reference ( 1) 
GTCox's (2) 0.665 0.338 1.94 l.OO, 3.77 0.050 Reference (2) 
Exponential (1) 0.810 0.323 2.24 1.19, 4.24 0.012 ~0-3; ~3-6; ~>6; ~zav 
Exponential (2) 0.734 0.335 2.08 1.07, 4.02 0.029 ~0-3; ~3-6; ~>6; ~zav 
Weibull (1) 0.738 0.309 2.09 1.15, 3.79 0.015 p; ~0-3; ~3-6; ~>6; ~zav 
Weibull (2) 0.722 0.3 17 2.05 1.10, 3.83 0.023 p; ~0-3; ~3-6; ~>6; ~zav 
Legend: AV access data from 535 individuals receiving 700 accesses and experiencing 
310 primary and 245 failures over 6 years. From each model the estimates of the 
interaction between late referral and heart failure are reported on the risk of primary (1) 
and secondary failure (2). Estimates are controlled for the effects of the main terms, 
access type, vascular disease and time band effects (0-3, 3-6, >6) for parametric models. 
fJ: beta coefficient (log-hazard difference); SE: standard error offJ; Exp(fJ) Hazard Ratio 
,· CJ95: 95% Confidence intervals of Exp(fJ); P value of the null hypothesis (fJ=O); GT: 
Conditional (Gap Time) Cox's models form previous event. As compared to the 
corresponding Cox's model the exponential model estimates 4 additional parameters: the 
effects of 3 time bands and access number ("zav"- used as stratifying variable in the 
Cox's models and thus not estimated); the Weibull model estimates 5 additional 
parameters: the effects of 3 time bands, access number and the shape parameter "p" 
(although only 2 time bands were necessary in this model - 0-6 and >6 - 3 bands were 
used for comparability). 
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entry) formulation9, the exponential model and the Weibull model. The Cox's models 
(for recurrent primary and final events) are considered the reference model for these data 
following the intention to identify prognostic factors and their estimated effects in terms 
of risk change. The model fit is excellent for both primary and secondary survival and 
neither assumption violations were found, nor significant residual problems. It can be 
seen from Table 23 that robust estimates under parametric constraints provide similar 
results (the log-hazard parameterization is chosen for comparability). However, both 
parametric models estimate extra-parameters: the intercept (hazard when the covariates 
are all zero), the effects of time band (2 necessary for the exponential model, and 1 only 
for the Weibull, although a second was included (even if not significant) for reasons of 
comparability), and the hazard change in second and further access versus the first (used 
as a stratifying variable in the Cox's model leaving its effect un-parameterized). There 
was no evidence of any covariate effects on the shape parameter ofthe Weibull model 10• 
Thus the Weibull model includes also one ancillary parameter "p" responsible for the 
model specific hazard shape (decreasing hazard, Figure 13). Had any covariate altered 
the hazard shape only, or both the shape and the scale of the hazard, its effect would have 
been estimated as shape parameter only or both as "p" specific in addition to the beta 
9 Results differ from those reported in Table 17 and Table 18 because of the different definition of the 
stratifying variable and the exclusion of the interaction term from the models reported in Table 18. As 
opposed to the models in Table 17 and Table 18 where the number of strata was equal to the maximum 
number of accesses received by the patients (four), the stratifying variable "access number" in the 
models reported in Table 23 and Table 24 was simplified to a two level variable (first versus subsequent 
A V accesses) because the baseline hazards of failure of the second, third and fourth access were similar. 
I 0 The Wei bull model allows one (or more) covariates to affect or even change the sign of the ancillary 
parameter log-pleading to two (or more) specific hazard shapes within the same model. 
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coefficient (shape or I and scale change). 
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Figure 13: Primary and secondary survival and hazard function from the robust variance 
Weibull regression model of the recurrent AV access data reported in Table 24. Higher 
survival curves refer to the presence of both late ref erral and heart failure; the other 
curves to the presence of either or none of such risk factors. 
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Thus the chosen parametric models provide estimates of the effect of interest at the cost 
of extra-parameter estimation work. Precision has not improved substantially in 
parametric models of primary survival, but the evidence in support of an effect of the 
exposure (interaction between heart failure and late referral) on secondary survival is 
clearly stronger. There are advantages deriving from the choice of parametric models 
when their hazard scale estimates are consistent with those from the reference Cox's 
model and the chosen model shape is consistent with the observed data (Figure 14). 
First, there are advantages in terms of power because more parameters can be estimated 
in parametric regression models than in the corresponding Cox's models. In fact the 
estimation method of the parametric models makes use of all the infonnation in the data 
and not only from the times when events occurred. Second when a phenomenon is 
sufficiently known to believe that a certain hazard shape can be modelled, estimates from 
parametric models are often more efficient (precise). Last, but not least, results can be 
expressed using the failure time interpretations and thus estimates and predictions of 
survival times can be obtained (Chapter 2). 
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Figure I 4: Observed primary and secondary recurrent event rate over time bands in 
months. 
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Frailty models 
Survival models can be used to estimate the unshared frailty or heterogeneity among 
observations (corresponding to the random effect variance estimated by the negative 
binomial model) and the shared frailty due to within subjects dependencies. Frailty 
models can be best understood comparing and contrasting these unshared and shared 
frailties, which is possible only for parametric models. In fact unshared frailty models for 
reasons of identifiability do not exist with Cox's regression because studying extra-
variability is impossible in the absence of any distributional assumptions. 
Estimates from unshared frailty models in Table 24 confirm the existence of important 
heterogeneity in the data as already noted from Cox's analyses (Chapter 5). This 
heterogeneity results from differences in the risk of failure (frailty) over observations 
unexplained by the fixed effects. When the frailty is modelled as shared, i.e. over 
clusters, the coefficient estimates are closer to those from the reference Cox's models 
(assuming that these are the true ones). In either case, the frailty is an unobserved 
multiplicative effect on the hazard function of the individual observation or cluster of 
observations assumed to follow some positive distribution (the hazard can not be 
negative). The variance parameter e of the random effects (over individual observations 
or clusters) is estimated from the data. As previously noted, stratification is an efficient 
method to control for the dependencies under the Cox's model (the variance of the 
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Table 24: Frailty survival models for continuous failure times data 
Models p SE Exp(p) Chs of Exp(p) P (P=O) Extra parameters 
US Expon. (I) 1.438 0.582 4.21 1.34, 13.2 0.013 > 0; (4) 
US Expon. (2) 1.418 0.643 4.13 1.16, 14.5 0.028 >0; (4) 
US Weibull (I) 1.402 0.574 4.06 1.31, 12.5 0.015 > 0; p(l); (4) 
US Weibull (2) 0.722 0.326 2.05 1.08, 3.90 0.027 = 0; p(l); (4) 
··-·········~--·-······ .. ·-·--·-···· .. --···-··--··-.. ·····-······--·--- ···········---·············--········-······-············-················- ····················--······-········"-··-------···········--··--·-···---·-··-····--······-··-·-- ........................................... ---····-··· 
SHU Cox's (I) 1.246 0.561 3.47 1.15, 10.45 0.026 > 0 
SHU Cox's (2) 0.963 0.554 2.63 0.88, 7.77 0.082 > 0 
SH C Cox's (I) 0.653 0.298 1.92 1.07, 3.45 0.029 = 0 
SH C Cox's (2) 0.606 0.328 1.83 0.96, 3.49 0.065 = 0 
SH Expon. (I) 1.641 0.584 5.16 1.64, 16.2 0.005 > 0; (4) 
SH Expon. (2) 1.326 0.563 3.76 1.24, 11.3 0.019 > 0; (4) 
SH Weibull (I) 1.251 0.487 3.49 1.34, 9.08 0.010 > 0; p(l); (4) 
SH Weibull (2) 0.995 0.474 2.70 1.06, 6.86 0.036 > 0; p(l); (4) 
Legend: AV access data (700 accesses in 535 subjects; 3I 0 primary and 245 secondary 
failures over 6 years). From each model the estimates of the interaction between late 
referral and heart failure are reported on the risk of primary (I) and secondary failure 
(2). Models controlled for the main terms, access type, vascular disease, access number 
and time band effects (0-3, 3-6, >6) for parametric models. fJ: beta coefficient (log-
hazard difference); SE: standard error of fJ; Exp(fJ) Hazard Ratio; CI95: 95% 
Confidence Intervals of Exp(fJ); P value of the null hypothesis (fJ=O); fJ: variance of the 
random effect; extra-parameters versus reference models in Table 23; US I SH: un-
shared I shared frailty models; U I C: unconditional I conditional (stratified) frailty 
Cox's regression. 
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random effect becomes zero after stratification). In the corresponding shared parametric 
regression models the point estimates are still larger. This may be due to the fact that the 
data are extremely unbalanced (Figure 2). When data are unbalanced due to random 
"missingness", maximum likelihood estimation takes into account the correlation in the 
data in the process of computation and works using available data to provide the best 
guess of what the data would be had they been fully available. When there are missing 
data, the ordinary least square estimate of the mean (which ignores random effects) is 
affected by the values of missing data (e.g., if larger values are missing the sample mean 
will underestimate the true parameter value). In random effects models, maximum 
likelihood estimation provides parameter estimates closer to those of the full data set 
prior to random data being lost or eliminated in simulation studies. 
An obvious question at this point is how to consider the current data set. Since data have 
been measured prospectively, data unbalance is the result of different subject frailty to 
succumb to disease and the limited observation time. Random effects models take into 
account the infonnation in the data and provide estimates of what would have happened 
had the follow-up been longer I the data complete. This must be interpreted with caution 
and prior knowledge about the failure process has a role in making choices. For example, 
for the A V access story one may hypothesize that thorough longitudinal measurements 
remain a false version of truth, and time constraints or even competing risks may have 
induced underestimation of the true effects. However, in other circumstances this may be 
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not the case and pragmatic approaches (including parametric robust models) may 
represent safer choices. 
Frailty parametric models offer other useful insights to clinical researchers. The ancillary 
parameter "p" of the primary robust Weibull survival model in Table 23 for example, is 
estimated at 0.45 (95% CI 0.4 to 0.49). The ancillary parameter implies that the 
"individual hazard" of primary failure is monotonically decreasing over time. In other 
words, as time passes by, the instantaneous risk of AV access failure each individual 
faces falls. If this is true, clinicians should tell their patients that if thrombosis has not 
taken place by a certain time after the AV access has been created then they need not 
worry too much as A V access failure is less likely as time goes by. On the other hand 
these estimates are obtained under the untenable assumption that all patients are identical 
other than the covariates in the model (late referral, heart failure, their interaction, access 
type, vascular disease and access number). When subjects differ in unobserved ways in 
their inherent risk to succumb (frailty) then the estimated ancillary parameter deserves 
more careful interpretation. The frailty version of the Weibull model of primary failure 
reported in Table 24 provides similar estimate of the ancillary parameter "p" (0.56, 95% 
CI 0.5 to 0.63) with significant variance "theta" of the frailty effects (2.2, from 1.4 to 
3.4). In some situations the frailty term affects substantially the shape of the individual 
hazard, in terms of value and I or sign of the (log) ancillary parameter, or even number of 
ancillary parameters (i .e., parameterization). In fact, frailty parametric models allow 
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estimating two hazard curves: one describing the individual hazard pattern, with shape 
belonging to the chosen family distribution, and the other describing the population 
pattern, which is usually decreasing over time. Although both the individual and the 
population hazard declined over time in the A V access study, the two curves may differ 
in some studies. For example, Cleves eta! re-analysed a dialysis catheter infection study 
using parametric models (30). They showed that according to the frailty Weibull model 
(which best fit the data), despite the fact that the population hazard for catheter infections 
initially increased after catheter placement and then fell as time passed by, the individual 
frailty monotonically increased (p > 1). In all frailty models individual and population 
hazards should be distinct because population and samples are heterogeneous. In fact in 
a heterogeneous population the population hazard can fall while the individual hazards all 
rise because over time more and more robust individuals survive while the more frail 
succumb. This phenomenon is known as frailty effect and results in a declining 
population hazard independent of the shape of the individual hazards. Parametric models 
allow exploration and distinction of these hazards as they may have different patterns 
when the variance of the frailty effect is significantly different from zero. These models 
may also be useful in the choice of the proper parameterization of the underlying failure 
risk process. Finally they tend to coincide as the variance of the frailty becomes zero 
because then the frailty model reduces to the standard regression model without frailty. 
A final important point should be made about the implications of the frailty term on 
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model assumptions and effects interpretation 11 • If a (shared) frailty component is added 
to Cox's regression then the PH assumption is not satisfied for the population hazard. 
The estimated HR are thus individual level effects. In other words, the HR are 
"conditional on the same level of frailty". Similarly, for parametric models it is 
important to consider the possible existence of a (shared or un-shared) frailty effect. In 
presence of a frailty effect the PH assumption is satisfied at the individual level but not at 
the population (unconditional) level. Conversely, the AFT assumption is satisfied at both 
levels 12• For this reason model checking and interpretation of a frailty model must take 
into account the possible existence of a frailty effect. 
I I The most popular distribution chosen for the frailty is the gamma distribution, but others exist such as 
the inverse-normal distribution. The choice of the distribution affects the interpretation of the fixed 
effects. For example, in hazard-metric frailty models the exponentiated coefficients are interpretable as 
hazard ratios when t = 0. After time zero, as more frail subjects leave the population at risk, differences 
in the fixed effects level off. In gamma frailty models this vanishing of the fixed effects is eventually 
complete in favour of the frailty effect. Conversely, in inverse-Gaussian frailty models the fixed effects 
never disappears but tend to the square root of the effects at time zero (30). 
12 The unconditional or population level hazard l..u(t) with gamma frailty is l..u(t) = A(t) I {I - Glog[S(t)]} . 
Population level hazard ratio HRu for one unit change of an exposure is l..u2(t) I AU I (t) = 1-!Ru. This 
H Ru is estimated as HRu = {1..2(t) I A I (t)} {I - Glog[S I (t)]} I {I - Glog[S2(t)]}, where A2(t) I 1.. I (t) = 
HR (PH) but where the last ratio is not constant as it depends on time. In the AFT metric the time ratio 
TR assumption holds instead because the unconditional survival probability Su(t) = {I - Glog[S(t)]} - 110• 
This implies that if S I (t) = S2(TR *t) then SuI (t) = {I - Glog[S2(TR *t)]} -Ito = Su2(TR *t). 
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7) Chapter 7: Conclusions 
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Chapter overview 
This concluding chapter presents an overview of the thesis work and summarizes the key 
concepts of risk estimation in longitudinal studies. 
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Risk estimation in longitudinal studies: challenges and opportunities 
Recurrent events of the same type (e.g., infections episodes) and multiple events of 
different type (e.g., myocardial infarction and renal failure) are often observed in 
longitudinal studies. Risk estimation of these failure events poses analytical challenges 
due to the correlation of repeated events in the same subject. A common approach to 
evaluate risk in longitudinal studies is to model time to first event using standard 
regression methods, and disregard further events once the first has occurred. This 
approach may not only reduce the study power but also lead to biased estimates. 
Analytical methods for recurrent or multiple events are available taking into account the 
lack of independence of repeated observations in the same epidemiological unit. 
In this thesis work the following steps are proposed for the design and analysis of 
longitudinal studies: 
Consideration of the characteristics of the failure event process; 
Identification of the possible reasons for the correlation in the data; 
Choice of the statistical model that best represents the failure event process; 
Organization of the data set to accomplish the analytical task. 
Consideration of the characteristics of the failure event process. It is important to 
understand whether the failure process generates ordered recurrent events of the same 
type or multiple unordered events of different type. The Vitamin D study in CKD was 
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used as an example of two competing events of different type. In that study, the exposure 
of interest (Vitamin D deficiency) was hypothesized to be involved in the mechanism of 
both failure processes, one leading to death and the other to dialysis initiation. As 
compared to standard Cox's regression of separate events (used as reference models), the 
composite event model provided biased estimate of the relative risk (HR) for death in 
Vitamin D deficient individuals (HR 2.26 v to 2.08). This is probably due to the fact that 
composite end point models disregard further events after the first. This may be wrong 
when data are correlated. Composite end point analysis is valid (including analysis of 
competing risks) when events are not correlated, i.e. when the likelihood of being 
censored at timet does not depend on the reason for censoring (including competing 
events). When events are correlated the likelihood of being censored at timet does 
depend on the reason for censoring. The advantage of the competing risk model, as 
opposed to separate single event models, is that when stratum specific effect estimates are 
very close to each other, single effects can be estimated for multiple events, and fewer 
parameters are estimated in the model. Similar considerations apply to ordered recurrent 
events of the same type. The reanalysis of the A V access study data shows that the 
analysis of the first event only leads to imprecise estimates. For example the existence of 
an interaction between heart failure and late nephrology referral on the risk of AV access 
failure was not supported by time to first event analysis (HR 1.96, 95% CI from 0.93 to 
4.1) but it was supported by recurrent event analysis (HR 2.02, 95% CI from 1.11 3.65). 
To model these recurrent events of the same type using a survival approach there are 
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several choices. However, most often the order condition and the difference in the 
baseline risks are important issues to be accounted for. For example, some models 
(marginal risk sets) are more appropriate for repeated hospitalizations, and other 
(conditional models) for repeated AV access failure or peritonitis episodes. 
Identification of the possible reasons for the correlation in the data. Biological and 
physio-pathological mechanisms for both subject heterogeneity and event dependence 
need to be carefully assessed. Both individual heterogeneity and event dependence can 
be sources of correlation in the data. In the presence of event dependence without 
important heterogeneity the true variance of the frailty is close to zero. This seemed the 
case in both data sets examined in this thesis. However, when the variance of the frailty 
is very small or not significantly different from zero one can use pragmatic approaches 
such as stratified variance-corrected methods within either a semi-parametric or 
parametric context. The un-stratified frailty Cox's model may detect a random effect 
signal which is really the consequence of event dependence rather than heterogeneity. In 
presence of heterogeneity without event dependence stratification would not be necessary 
since the baseline risk does not change by event number. In this case variance corrected 
models may be inefficient and the unconditional frailty model would perform better. Yet, 
if repeated events data exhibit both heterogeneity and dependence, a stratified frailty 
model would be highly desirable. 
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Choice of the statistical model that best represents the failure event process. When there 
are reasons to believe that the risk change over time can be described well by some 
theoretical hazard distribution, then the choice of a parametric model may offer several 
advantages. Using the Cox's model as gold standard to check the amount of possible bias 
and consistency, one can check the information gain deriving from the inclusion of 
multiple and repeated events and the improvement in efficiency. Time can be split into 
pieces to control the change in rates as time goes by. This approach was shown using the 
A V access data. The Weibull distribution was found to describe the recurrent failure 
process well. Parametric survival models offer additional advantages in terms of effect 
interpretation (time metric) and individual v population hazard (frailty effect). 
Organization of the data set to accomplish the analytical task. Risk sets organization is 
critical to event history analysis. However, even for count data analysis it is always 
necessary to define the time exposure correctly. Using the AV access data several data 
set ups were shown for different analytical purposes including models for cow1t data. 
Usually investigators base their choices on assumptions about when the risk starts, 
changes and ends. Another example may be useful. If time to central venous catheter 
infection is measured and repeated episodes can occur in the same subject, it is important 
to know whether or not a plan is in place to remove the catheter, clear each infection 
episode and allow some additional time to pass before a new catheter is inserted and the 
patient returns at risk. This plan may make the assumption of resetting the risk clock 
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back to zero reasonable because the new catheter insertion date marks the risk onset for a 
new event and recurrence time is measured as time elapsed from this risk onset date 
rather than from the study start date. In other circumstances (e.g., no catheter removal 
and replacement, limited treatment time after each catheter infection episode) the risk 
clock is never reset, time is measured continuously from entry into the study while 
recurrences occur over time, and the risk accumulates from entry. It is important to make 
clear that the way analysis time is measured to set up the risk sets is based on clinical or 
biological considerations reflecting the dynamic and nature of the failure process rather 
than statistical assumptions. 
In conclusion, different issues need to be considered in the design and analysis of 
longitudinal studies. These include a thorough evaluation of the biology and mechanisms 
of the failure event process, careful identification of the possible sources of correlation in 
the event data, and correct choice of the statistical model that best represent the 
phenomenon under study. This stepwise approach enhances the likelihood of successful 
generation and analysis of complex longitudinal data. 
132 
8) References 
133 
I. Ravani P, Marcelli D, Pecchini P, Malberti F: Early failure rates of arterovenous 
fistulas for hemodialysis: evaluation of six-year activity, J Vase Access 2: 154-160,2001 
2. Ravani P, Marcelli D, Malberti F: Vascular Access Surgery Managed by Renal 
Physicians: the Choice of Native Arterovenous Fistulas for Hemodialysis. Am J Kidney 
Dis40: 1264-1276,2002 
3. Ravani P, Brunori G, Mandolfo S, Cancarini G, Imbasciati E, Marcelli D, Malberti F: 
Cardiovascular comorbidity and late referral impact arteriovenous fistula survival: a 
prospective multicenter study. JAm Soc Nephrol 15:204-9, 2004 
4. Ravani P, Barrett B, Mandolfo S, Brunori G, Cancarini G, lmbasciati E, Malberti F: 
factors associated with unsuccessful utilization and early failure of the arteriovenous 
fisula for hemodialysis. J Nephrol 2005 Mar-Apr; 18(2): 188-96 
5. Ravani P, Malberti F, Tripepi G, Testa S, Mallamaci F, Zoccali C: Asymmetrical Di-
Methyl-Arginine (ADMA) predicts progression to dialysis and death in patients with 
Chronic Kidney Disease (CKD): a competing risks modeling approach. J Am Soc 
Nephrol. 2005 Aug; 16(8):2449-55 
6. Scolari F, Ravani P, et al: The Challenge of Diagnosing Atheroembolic Renal Disease: 
Clinical Features and Prognostic Factors, Circulation: 17; 116(3):298-304 
7. Ravani P, Tripepi G, Pecchini P, Mallamaci F, Malberti F, Zoccali C: Urotensin II is 
an Inverse Predictor of Death and Cardiovascular Events in Chronic Kidney Disease, 
Kidney Int. 2007 Oct 17 
8. Ravani P, Malberti F, Tripepi G, Pecchini P, Mallamaci F, Cutrupi S, Pizzini P, 
134 
Zoccali C: Vitamin D Levels and Patient Outcomes in Chronic Kidney Disease: a 
Longitudinal Cohort Study. Kidney lnt, 2009;75(1):88-95 
9. Ravani P, Parfrey PS, Curtis B, Barrett BJ: Clinical Research of Kidney Diseases 1: 
Researchable Questions and Valid Answers, Nephrol Dial Transplant. 2007 
Sep;22(9):2459-68 
10. Ravani P, Parfrey PS, Dicks E, Barrett BJ: Clinical Research of Kidney Diseases II: 
Problems of Study Design, Nephrol Dial Transplant. 2007 Oct;22(1 0):2785-94 
11. Ravani P, Parfrey PS, Gadag V, Malberti F, Barrett BJ: Clinical Research of Kidney 
Diseases III: Principles of Regression and Modeling. Nephrol Dial Transplant, 
2007;22:3422-30 
12. Ravani P, Parfrey PS, Gadag V, MurphyS, Barrett BJ: Clinical Research of Kidney 
Diseases IV: Standard Regression Models. Nephrol Dial Transplant, 2008;23(2):475-82 
13. Ravani P, Parfrey PS, Gadag V, Malberti F, Barrett BJ: Clinical Research of Kidney 
Diseases V: Extended Analytic Methods. Nephrol Dial Transplant. 2008 
May;23(5): 1484-92 
14. Ravani P, Spergel LM, Asif A, Roy-Chaudhury P, Besarab A: Clinical epidemiology 
of arteriovenous fistula in 2007. J Nephrol, 2007; 20:141-9 
15. Roy-Chaudhury P, Spergel LM, Besarab A, Asif A, Ravani P: Biology of 
arteriovenous fistula failure. J Nephrol, 2007;20: 150-63 
16. Lawrence M. Spergel, Pietro Ravani, Prabir Roy-Chaudhury, Arif Asi, Anatole 
Besarab: Autogenous Arteriovenous Fistula Options, J Nephrol. 2007;20(3):288-98 
135 
17. Arif Asif, Pietro Ravani, Prabir Roy-Chaudhury, Lawrence M. Spergel, Anatole 
Besarab: Vascular Mapping Techniques: Advantages and Disadvantages, J Nephrol. 
2007;20(3):299-303 
18. Anatole Besarab, Arif Asif, Prabir Roy-Chaudhury, Lawrence M. Spergel, Pietro 
Ravani: AVF in 2007: Surveillance and Monitoring, J of Nephrology. 2007;20:656-67 
19. Asif A, Besarab A, Roy-Chaudhury P, Spergel LM, Ravani P: Interventional 
nephrology: from episodic to coordinated vascular access care. J Nephrol. 
2007;20(4):399-405 
20. Spergel LM, Ravani P, Roy-Chaudhury P, Asif A, Besarab A: Surgical salvage of the 
autogenous arteriovenous fistula (AVF). J Nephrol. 2007;20(4):388-98 
21. Anatole Besarab, Pietro Ravani, Lawrence M. Spergel, Prabir Roy-Chaudhury, Arif 
Asif,: A VF in 2007: Research Needs, J of Nephrology. 2007;20:668-73 
22. LinDY, Wei LJ: The robust inference for the Cox proportional hazards model. 
Journal ofthe American Statistical Association 84:1074-1078, 1989 
23. Therneau TM, Grambisch PM: Modeling Survival Data: Extending the Cox Model. 
Springer-Verlag: New York, 2000 
24. Huang X, Wolfe RA: A frailty model for informative censoring. Biometrics 58:510-
520,2002 
25. Box-Steffensmeier JM, De BoefS: Repeated events survival models: the conditional 
frailty model. Stat Med Dec [Epub ahead of print], 2005 
26. Andersen PK, Gill RD: Cox's regression model for counting processes: A large 
136 
sample study. Annals of Statistics 10: 1100-1120, 1982 
27. Wei LJ, LinDY, Weissfeld L: Regression analysis of multivariate incomplete failure 
time data by modeling marginal distributions. Journal of the American Statistical 
Association 84: 1065- 1073, 1989 
28. Lunn M, McNeil D: Applying Cox regression to competing risks. Biometrics 51: 
524-532, 1995 
29. Prentice RL, Williams BJ, Peterson AV: On the regression analysis of multivariate 
failure time data. Biometrika 68: 373- 379, 1981 
30. Cleves MA, Gould WW, Gutierrez RG: Generalizing the Parametric Regression 
model, in "An Introduction to Survival Analysis using STAT A", pp 269-298, STAT A 
press publication, College Station Texas, ftrst revised edition, 2004 
137 
9) Further reading 
Glantz SA, Slinker BK: A Primer of Applied Regression and Analysis of Variance. Me 
Grow Hill, 2001 (second edition) 
Kleinbaum DG, Kupper LL, Muller KE, Nizam A: Applied Regression Analysis and 
Multivariable Methods. Duxbury Press 1997 
Dupont WD: A simple introduction to the analysis of complex data. Cambridge 
University Press 2002 
Hosmer DW, Lemeshow S: Applied Logistic Regression. John Wiley and Sons, 2000 
Cox DR: Regression Models and Life-Tables. Journal of the Royal Statistical Society, 
Series B, 1972; 34: 187- 220 
Hosmer DW, Lemeshow LS: Applied Survival Analysis, Regression Modelling of Time 
to Event Data, John Wiley & Sons, New York: 1999 
Kleinbaum DG: Survival Analysis, a Self-Learning Text, Springer-Verlag, New York: 
2005 
West B, Welch K, Galecki AT: Linear Mixed Models: A Practical Guide using Statistical 
Software. Chapman & Haii/CRC, New York: 2007 
Themeau TM, Grambisch PM: Extending the Cox Model. Springer-Verlag, New York: 
2000 
138 



